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INTRODUCTION 
 
DRUG DELIVERY SYSTEMS1, 2 
A drug delivery system (DDS) is defined as a formulation or a device that 
enables the introduction of a therapeutic substance in the body and improves its 
efficacy and safety by controlling the rate, time, and place of release of drugs in the 
body. Drug delivery system is an interface between the patient and the drug. It may be 
a formulation of the drug to administer it for a therapeutic purpose or a device used to 
deliver the drug.  
When a drug is taken by a patient, the resulting biological effects are 
determined by the pharmacological properties of the drug. These biological effects are 
usually produced by an interaction of the drug with specific receptors at the drug‟s 
site of action. However, unless the drug can be delivered to its site of action at a rate 
and concentration that both minimizes side- effects and maximizes therapeutic effects, 
the efficiency of the therapy is compromised. In some cases, delivery and targeting 
barriers may be so great as to preclude the use of an otherwise effective drug 
candidate. 
The method by which a drug is delivered can have a significant effect on its 
efficacy. Some drugs have an optimum concentration range within which maximum 
benefit is derived, and concentrations above or below this range can be toxic or 
produce no therapeutic benefit at all. On the other hand, the very slow progress in the 
efficacy of the treatment of severe diseases, has suggested a growing need for a 
multidisciplinary approach to the delivery of therapeutics to targets in tissues. From 
this, new ideas on controlling the pharmacokinetics, pharmacodynamics, non-
specific toxicity, immunogenicity, biorecognition, and efficacy of drugs were 
generated. These new strategies, often called drug delivery systems (DDS), are based 
on interdisciplinary approaches that combine polymer science, Pharmaceutics, 
bioconjugate chemistry, and molecular biology.
2
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NOVEL DRUG DELIVERY SYSTEM
3 
          The aim of Novel Drug Delivery System is to provide a therapeutic amount of 
drug to the appropriate site in the body to accomplish promptly and then maintain the 
desired drug concentration. The drug delivery system should deliver drug at a rate 
control by the necessarily of the body over a specified term of treatment. 
A number of novel drug delivery system has emerged encompassing various 
routes of administration, to achieve controlled and targeted drug delivery. 
Encapsulation of the drug in vesicular structure is one such system, which can be 
predicted to prolong the existence of the drug in systemic circulation and reduce the 
toxicity if selective uptake can be achieved. Consequently a number of vesicular drug 
delivery system such as liposomes, niosomes, transfersomes and pharmacosomes 
were developed. Advances have since been made in the area of vesicular drug 
delivery, leading to the development of this system that allow drug targeting and 
sustained or controlled release of conventional drug medicines.
 
For many decades treatment of an acute disease or a chronic illness has been 
mostly accomplished by delivery of drugs to patients using various pharmaceutical 
conventional dosage forms. Even today conventional drug delivery system occupies 
most of the part in a prescription as well as drug store. This type of drug delivery 
system is known to provide a prompt release of drug. But to achieve as well as to 
maintain the drug concentration within the therapeutically effective range needed for 
treatment, it is often necessary to take this type of drug delivery system several times 
a day. This results in significant fluctuations in drug level.
 
DISADVANTAGES OFCONVENTIONAL DOSAGE FORMS
3 
i. Drugs with short half- life require frequent administration, which increases 
chances of missing the dose of a drug leading to poor patient compliance. 
ii. A typical peak- valley plasma concentration- time profile is obtained 
which makes attainment of steady state condition very difficult. 
iii. The unavoidable fluctuations in the drug concentration may lead to under- 
medication or over- medication as the Css values fall or rise beyond the 
therapeutic range which may lead to adverse effects of the drug. 
iv. Drug accumulation may occur in case of the frequent administration of the 
drugs. 
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To overcome the above drawbacks, drug delivery systems capable of 
controlling the rate of drug delivery, sustaining the duration of therapeutic action 
and/ or targeting the drug to a particular tissue was developed.  
The novel drug delivery systems are diversely referred to as “controlled 
release”, “sustained release”, “zero- order”, “reservoir”, “monolithic”, 
“membrane- controlled”, “smart”, “stealth” etc. some of these common terms are 
defined as follows:
 
 Prolonged/ sustained release: the delivery system prolongs therapeutic blood 
or tissue levels of the drug for an extended period of time. 
 Zero order release: the drug release does not vary with time; thus the 
delivery system maintains a (relatively) constant effective drug level in the 
body for prolonged periods. 
 Variable release: the delivery system provides drug input at a variable rate, to 
match, for example endogenous circadian rhythms, or to mimic natural 
biorhythms. 
 Bio- responsive release: the system modulates drug release in response to a 
biological stimulus (e.g. blood glucose levels triggering the release of insulin 
from a drug delivery device) 
 Modulated/ self regulated release: the system delivers the necessary amount 
of drug under the control of the patient.  
 Rate- controlled release: the system delivers the drug at some pre- 
determined rate, whether systemically or locally, for a specific period of time. 
 Targeted- drug delivery: the delivery system achieves site- specific drug 
delivery. 
 Temporal- drug delivery: the control of delivery to produce an effect in a 
desired time- related manner. 
 Spatial- drug delivery: the delivery of a drug to a specific region of the body 
(thus this term encompasses both route of administration and drug 
distribution). 
 Bioavailability: the rate and extent at which a drug is taken up into the body. 
 Repeat action: individual dose is released fairly soon after administration and 
second or third doses are subsequently released at intermittent intervals. 
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TARGETED/ SITE- SPECIFIC DRUG DELIVERY SYSTEM
 4 
While rate- controlled systems can deliver the drug at a predetermined 
rate, they are generally unable to control the fate of the drug, once it enters the 
body. Targeted drug delivery system refers to systems that place the drug at or 
near the receptor site or site of action. Targeted drug delivery implies selective 
and effective localization of drug into the target(s) at therapeutic concentrations 
with limited access to target sites.
 
Site- specific drug delivery is desirable in therapeutics, in order to 
improve:
 
 Drug safety, as toxic side- effects caused by drug action at non- target sites are 
minimized. 
 Drug efficacy, as the drug is concentrated at the site of action rather than 
being dispersed throughout the body. 
 Patient compliance, as increased safety and efficacy should make therapy 
more acceptable and thus improve compliance. 
Technologies for drug targeting are concerned with delivering drugs to 
specific targets in the body and also to protect drugs from degradation and 
premature elimination. They include the use of 
 Soluble carriers, such as monoclonal antibodies, dextrans, soluble synthetic 
polymers 
 Particulate carriers, such as liposomes, niosomes, micro- and nano- particles, 
microspheres 
 Target- specific recognition moieties, such as monoclonal antibodies, 
carbohydrates and lecithins. 
Recent advances in biological and chemical sciences have led to the 
development of various “smart” technologies to ensure more effective drug 
delivery and targeting of drugs to specific sites within the body. Such approaches 
include the use of: 
 Antibody- directed enzyme/ prodrug therapy (ADEPT) 
 Virus- directed prodrug/ enzyme therapy (VDEPT) 
 Chemical drug delivery systems 
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DRUG DELIVERY CARRIERS
 2 
Colloidal drug carrier systems such as micellar solutions, vesicle and 
liquid crystal dispersions, as well as nanoparticle dispersions consisting of small 
particles of 10–400 nm diameter show great promise as drug delivery systems. 
When developing these formulations, the goal is to obtain systems with optimized 
drug loading and release properties, long shelf-life and low toxicity. The 
incorporated drug participates in the microstructure of the system, and may even 
influence it due to molecular interactions, especially if the drug possesses 
amphiphilic and/or mesogenic properties. 
Fig:1 Pharmaceutical carriers 
 
 
   
VESICULAR DRUG DELIVERY SYSTEMS
5 
The vesicular systems are highly ordered assemblies of one or several 
concentric lipid bilayers formed, when certain amphiphillic building blocks are 
confronted with water. Vesicles can be formed from a diverse range of 
amphiphillic building blocks. Biologic origin of these vesicles was first reported 
in 1965 by „Bingham‟ and has been given the name Bingham bodies. 
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Now a days, vesicles as a carrier system have become the vehicle of choice 
in drug delivery and lipid vesicles were found to be of value in immunology, 
membrane biology and diagnostic technique and most recently in genetic 
engineering. Vesicular delivery system provides an efficient method for delivery 
to the site of infection, leading to reduce of drug toxicity with no adverse effects. 
Vesicular drug delivery reduces the cost of therapy by improved bioavailability of 
medication, especially in case of poorly soluble drugs. They can incorporate both 
by hydrophilic and lipophilic drugs. Different novel approaches used for 
delivering the drugs by vesicular system include liposomes, niosomes, 
sphingosomes, transfersomes and pharmacosomes. 
Encapsulation of a drug in vesicular structures can be predicted to prolong 
the existence of the drug in systemic circulation, and perhaps, reduces the toxicity 
if selective uptake can be achieved. Lipid vesicles are one type of many 
experimental models of biomembranes which evolved successfully, as vehicles for 
controlled delivery. For the treatment of intracellular infections, conventional 
chemotherapy is not effective, due to limited permeation of drugs into cells. This 
can overcome by the use of vesicular drug delivery systems.
 
ADVANTAGES OF VESICULAR DRUG DELIVERY
 5 
1. Prolong the existence of the drug in systemic circulation, and perhaps, 
reduces the toxicity if selective uptake can be achieved due to the delivery 
of drug directly to the site of infection. 
2. Improves the bioavailability especially in the case of poorly soluble drugs. 
3. Both hydrophilic and lipophilic drugs can be incorporated. 
4. Delays elimination of rapidly metabolizable drugs and thus function as 
sustained release systems. 
These vesicular systems are accompanied with some problems like drug 
carriers and externally triggered (eg., temperature, pH, or magnetic sensitive) 
carriers load drugs passively, which may lead to low drug loading efficiency and 
drug leakage in preparation, preservation and transport in- vivo. Need of intensive 
sonication, lead to leakages of drug during storage. Thus the major problem of 
their stability acts as a barrier and thus limiting their use.
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The targeted vesicles are classified on the basis of their composition as
 
 Lipoidal biocarriers 
 Liposomes  
 Emulsomes  
 Enzymosomes 
 Ethosomes 
 Sphingosomes 
 Transfersomes 
 Pharmacosomes 
 Virosomes  
 Non- lipoidal biocarriers 
i. Niosomes 
ii. Bilosomes 
iii. Aquasomes  
LIPOSOMES
 9 
Liposomes or lipid based vesicles are microscopic (unilamellar or 
multilamellar) vesicles that are formed as a result of self-assembly of 
phospholipids in an aqueous media resulting in closed bilayered structures. The 
assembly into closed bilayered structures is a spontaneous process and usually 
needs some input of energy in the form of physical agitation, sonication, heat etc. 
Since lipid bilayered membrane encloses an aqueous core, both water and lipid 
soluble drugs can be successfully entrapped into the liposomes.  
The lipid soluble or lipophilic drugs get entrapped within the bilayered 
membrane whereas water soluble or hydrophilic drugs get entrapped in the central 
aqueous core of the vesicles. For drug delivery applications liposomes are usually 
unilamellar and range in diameter from about 50 – 150 nm. Larger liposomes are 
rapidly removed from the blood circulation. Liposomes are unique in their ability 
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to accommodate drugs, which differ widely in physicochemical properties such as 
polarity, charge and size. (vesicular stability issues) 
NIOSOMES
 5 
Niosomes are a novel drug delivery system, in which the medication is 
encapsulated in a vesicle. The vesicle is composed of a bilayer of non-ionic 
surface active agents and hence the name niosomes. The niosomes are very small, 
and microscopic in size. Their size lies in the nanometric scale. Niosomes are non-
ionic surfactant vesicles obtained on hydration of synthetic nonionic surfactants, 
with or without incorporation of cholesterol or other lipids. They are vesicular 
systems similar to liposomes that can be used as carriers of amphiphillic and 
lipophillic drugs.  Although structurally similar to liposomes, they offer several 
advantages over them. 
Advantages 
 Better patient compliance and better therapeutic effect in comparison to oily 
formulations. Can be used to deliver hydrophilic, lipophilic as well as 
amphiphilic drugs and can accommodate drugs with wide range of solubility. 
 Controlled and sustained release of drugs due to depot formation. Enhance the 
oral bioavailability of drugs. 
 Osmotically  active and stable. 
 Biocompatible,  biodegradable, non-toxic and non-immunogenic. Protect the 
drug from enzymatic metabolism thus increases the stability of drug 
 Drug targeting  to various organs. 
 Enhance the skin  permeation of drugs. 
 Easy to handle, store and transport. 
 Administered by various routes via oral, parenteral, topical etc. 
 The shape, size, composition and fluidity of niosomes can be controlled as and 
when required. 
PHARMACOSOMES
 5 
These are defined as colloidal dispersions of drugs covalently bound to 
lipids and may exist as ultrafine vesicular, micellar or hexagonal aggregates, 
depending on the chemical structure of drug-lipid complex15. The prodrug 
conjoins hydrophilic and lipophilic properties and therefore acquires amphiphillic 
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characters and was found to reduce interfacial tension and thus at higher 
concentrations exhibits mesomorphic behavior. Because the system is formed by 
linking a drug (pharmakon) to a carrier (soma), they are called pharmacosomes. 
Pharmacosomes bearing unique advantages over liposome and niosome vesicles 
have come up as potential alternative to conventional vesicles. 
ETHOSOMES
 9 
Ethosomes are noninvasive delivery carriers that enable drugs to reach the 
deep skin layers and/or the systemic circulation. These are soft, malleable vesicles 
tailored for enhanced delivery of active agents. They are composed mainly of 
phospholipids (phosphatidylcholine, phosphatidylserine, phosphatitidic acid), high 
concentration of ethanol and water. The high concentration of ethanol makes the 
ethosomes unique, as ethanol is known for its disturbance of skin lipid bilayer 
organization therefore, when integrated into a vesicle membrane it gives that 
vesicle the ability to penetrate the stratum corneum. Also because of their high 
ethanol concentration, the lipid membrane is packed less tightly than conventional 
vesicles but has equivalent stability, allowing a more malleable structure and 
improves drug distribution ability in stratum corneum lipids. 
TRANSFERSOMES
 9 
Transfersomes are specially optimized, ultradeformable (ultraflexible) 
lipid supramolecular aggregates, which are able to penetrate the mammalian skin 
intact. Each transfersome consists of at least one inner aqueous compartment, 
which is surrounded by a lipid bilayer with specially tailored properties, due to the 
incorporation of "edge activators" into the vesicular membrane. Surfactants such 
as sodium cholate, sodium deoxycholate, span 80 and Tween 80, have been used 
as edge activators. It was suggested that transfersomes could respond to external 
stress by rapid shape transformations requiring low energy. These novel carriers 
are applied in the form of semi-dilute suspension, without occlusion. Due to their 
deformability, transfersomes are good candidates for the non-invasive delivery of 
small, medium and large sized drugs. They have been used as drug carriers for a 
range of small molecules, peptides, proteins and vaccines, both in vitro and in 
vivo.  
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Materials commonly used for the preparation of transfersomes are 
phospholipids (soya phosphatidyl choline, egg phosphatidyl choline), surfactant 
(tween 80, sodium cholate) for providing flexibility, alcohol (ethanol, methanol) 
as a solvent, dye for confocal scanning laser microscopy (CSLM) and buffering 
agent (saline phosphate buffer pH 7.4), as a hydrating medium. 
COLLOIDOSOMES
 9 
Colloidosomes are the hollow shell microcapsules consisting of coagulated 
or fused particles at interface of emulsion droplets. Colloidosomes have exciting 
potential applications in controlled release of drugs, proteins, vitamins as well as 
in cosmetics and food supplements. Colloidosomes have a great encapsulation 
efficacy with a wide control over size, permeability, mechanical strength and 
compatibility. Colloidosomes assemble polymer latex colloidal particles into 
shells around water-in-oil emulsion drops followed by partial fusion of shell and 
centrifugal transfer into water to yield stable capsules in which the shell 
permeability can be controlled by adjustment of partial fusion conditions. Hairy 
colloidosomes whose shell consists of microrod particles, are designed and 
fabricated novel colloidosome capsules that consist of aqueous gel core and shells 
of polymeric microrods. This has been achieved by templating water-in-oil 
emulsions stabilized by rod like particles followed by gelling of the aqueous 
phase, dissolution of oil phase in ethanol and redispersion of obtained 
colloidosome microcapsules in water. 
HERBOSOMES
 9 
The term "herbo" means plant, while "some" means celllike. Over the past 
century, phyto-chemical and phyto-pharmacological sciences established the 
compositions, biological activities and health promoting benefits of numerous 
botanical products. Most of the biologically active constituents of plants are polar 
or water soluble molecules. However, water soluble phytoconstituents (like 
flavonoids, tannins, glycosidic aglycones etc) are poorly absorbed either due to 
their large moleculer size which cannot be absorbed by passive diffusion, or due 
to their poor lipid solubility, severely limiting their ability to pass across the 
lipidrich biological membranes, resulting in poor bioavailability. Phytomedicines, 
complex chemical mixtures prepared from plants, have been used for health 
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maintenance since ancient times. But many phytomedicines are limited in their 
effectiveness because they are poorly absorbed when taken by mouth. 
Herbosomes are also often known as phytosomes. Molecular layer consisting of 
PC and other phospholipids provides a continuous matrix into which the proteins 
insert. 
SPHINGOSOMES
 9 
Sphingosomes are concentric, bilayered vesicle in which an aqueous 
volume is enclosed by a membranous lipid bilayer mainly composed of natural or 
synthetic sphingolipids. Sphingosomes are comprised of sphingolipids and 
cholesterol, an interior aqueous environment having pH less than that of exterior. 
The drug is encapsulated inside the lipid bilayer and is delivered to the host at a 
predetermined rate thereby improving the efficacy, increasing the circulation time 
and reducing the toxicity. Sphingosomes can be utilized for therapeutic, cosmetic 
and diagnostic purpose for the delivery of active to the target site or organ.  
They can be administered by variety of routes like oral, parenteral, 
inhalation, transdermal etc. Sphingolipid present in the sphingosomes offer 
several advantages to these vesicular systems for targeting both by passive and 
active targeting mechanism. 
CUBOSOMES
 9 
Bicontinuous cubic liquid crystalline materials are active ingredients 
because they give the unique structural ends to controlled release applications. 
Amphiphillic molecules form bicontinuous water and oil channels, where 
“bicontinuous” refers to two distinct (continuous, but non-intersecting) 
hydrophilic regions separated by the bilayer. Cubosomes are discrete, sub micron, 
nanostructured particles of bicontinuous cubic liquid crystalline phase. 
Cubosomes possess the same microstructure as the parent cubic phase but have 
much larger specific surface area and their dispersions have much lower viscosity 
than the bulk cubic phase. The ability of cubic phases to exist as discrete dispersed 
colloidal particles or cubosomes is perhaps the most intriguing. Whereas most 
concentrated surfactants that form cubic liquid crystals lose these phases to 
micelle formation at high dilutions, a few surfactants have optimal water 
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insolubility. Their cubic phases exist in equilibrium with excess water and can be 
dispersed to form cubosomes. 
LAYEROSOMES
 9 
The layer-by-layer coating concept is one of the strategies used for the 
preparation or the stabilization of nanosystems. The layersomes are conventional 
liposomes coated with one or multiple layers of biocompatible polyelectrolytes in 
order to stabilise their structure. The formulation strategy is based on an 
alternative coating procedure of positive poly (lysine) (pLL) and negative poly 
(glutamic acid) (pGA) polypeptides on initially charged small unilamellar 
liposomes. Oral administration or their incorporation in biomaterials is among 
potential fields of application. 
UFASOMES
 9 
The fatty acid vesicles are named "ufasomes," ufosomes are unsaturated 
fatty acid liposomes. Fatty acid vesicles are colloidal suspensions of closed lipid 
bilayers that are composed of fatty acids and their ionized species (soap). They are 
observed in a small region within the fatty acid-soap-water ternary phase diagram 
above the chain melting temperature (Tm) of the corresponding fatty acid-soap 
mixture. Fatty acid vesicles always contain two types of amphiphiles, the 
nonionized neutral form and the ionized form (the negatively charged soap). The 
ratio of nonionized neutral form and the ionized form is critical for the vesicle 
stability. Fatty acid vesicles are actually mixed "fatty acid/soap vesicles". 
Ufasome membranes are much more stabilized in comparison to liposomes. 
CRYPTOSOMES
 11 
Stealth liposomes, also known as immune-liposomes or cryptosomes are 
liposomes that evade detection in an immune system. Stealth liposomes or 
cryptosomes are designed to circulate for longer periods of time in- vivo, but they 
are different from "long-circulating liposomes". Stealth liposomes use 
polyethylene glycol (PEG) as a steric stabilizer. The properties of the stealth 
liposome depend on the way PEG is linked to the lipids. It is important to note 
that stealth liposomes are not fully inert vesicles; they can eventually become 
detected by the immune system. It could be used for slow release of drug or for 
imaging purposes. Incorporation of polymers, such as polyethylene glycol-lipid 
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derivatives, or glycolipids into liposomes results in sterically stabilized liposomes 
which have several advantages over liposome formulations traditionally used in 
the past, including reduced recognition and uptake by macrophages, extended 
circulation half-lives, targeted drug delivery dose-independent pharmacokinetics, 
and increased uptake in- vivo by solid tumors, breast cancer. 
ULTRASOMES
 11 
Ultrasomes are specialized liposomes encapsulating an endonuclease 
enzyme extracted from Micrococcus luteus. Endonuclease recognizes ultra violet 
(UV) damage and is reported to accelerate its repair four-folds. Ultrasomes also 
protect the immune system by repairing UV-DNA damage and reducing the 
expression of tumor necrosis factor (TNF-α), interleukins (IL-1, IL-6 and IL-8). 
They stimulate the production of melanin by melanocytes in the tanning response 
following UV exposure and are used in cosmeceuticals and anti-aging 
formulations. 
PHOTOSOMES
11 
These are artificial spherical submicroscopic vesicles with diameter 
between 25 and 5000 nm. Photosomes are composed of amphiphilic molecules 
with core that consists of an aqueous cavity, which is encapsulated by one or more 
bimolecular phospholipid sheets separated from each other by aqueous layers. 
Photosomes contain the enzyme photolysase encapsulated in a liposome structure 
and are incorporated in sun-care product to protect the sun exposed skin by 
releasing a photo-reactivating enzyme extracted from a marine plant, Anacystis 
nidulans. This enzyme can be activated by light and can work during the day to 
support the skin deoxyribonucleic acid (DNA) repair process.  
Combined with ultrasomes, they constitute the "intelligent" DNA repair 
system and are the most widely used in cosmetic delivery systems and 
photodynamic therapy. 
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EMULSOME
11 
Emulsomes are a new generation of colloidal carrier systems in which 
internal core is made of fats and triglycerides which is stabilized by high 
concentration of lecithin in the form of o/w emulsion. Emulsomes have the 
characteristics of both liposomes and emulsions. The solidified or semi-solidified 
internal oil core provides a better opportunity to load lipophilic drugs in high 
concentrations. Simultaneously, a prolonged controlled release can also be 
expected and the ability to encapsulate water-soluble medicaments in the aqueous 
compartments of surrounding phospholipid layers. The solvent free and surfactant 
free emulsomes technology have demonstrated high drug en-capsulation capacity 
for water insoluble antifungal and anticancer drugs showing enhanced drug 
delivery and improved preclinical efficacy for parenteral routes. 
GENOSOMES
11 
Genosomes are complex of genetic material like DNA and suitable lipid. 
They are also known as lipoplexes that are used to deliver genes. They are 
artificial macromolecular complexes for functional gene transfer. Cationic lipids 
are most suitable for this delivery system because they possess high 
biodegradability and stability in the blood stream. Mostly DNA-cationic liposome 
complexes were used to translocate DNA across cellular membranes in- vivo, 
because interaction between DNA-lipid membranes has proved crucial to the 
understanding of the colloidal state of the genosomes. These DNA lipid 
complexes could be later aggregated into higher order assemblies, creating 
stacked lipid-DNA multilayers, for generating more protection. 
VIROSOMES
11 
Virosomes are reconstituted viral envelopes including membrane lipids 
and viral spike glycoproteins but devoid of viral genetic material. The external 
surface of the virosome resembles that of a virus particle with spike proteins 
protruding from the membrane but their interior compartment is empty. 
Virosomes were first prepared with inserted purified influenza spike proteins into 
preformed liposomes. Thereafter a range of viral envelopes have been 
reconstituted including those of Sendai virus, Semliki Forest Virus (SFV), 
Vesicular Stomatitis Virus (VSV) and Sindbis virus. Because virosomes display 
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viral envelope glycoproteins which in their native conformation stimulate humoral 
responses, they are highly effective as vaccine antigens and adjuvants. 
ENZYMOSOME
11 
The structure in which an enzyme is enclosed in a liposome is called an 
enzymosome. These are liposomal constructs engineered to provide a mini 
bioenvironment in which enzymes are covalently immobilized or coupled to the 
surface of the liposomes thereby targeting the drugs to the tumor cells. 
VESOSOME
11 
Vesosomes are multicompartment structures which has distinct inner 
compartments separated from the external membrane. Each compartment of 
vesosome can encapsulate different materials and have different bilayer 
composition. Vesosome could entrap both colloidal particles and bio-logical 
macromolecules relatively efficiently. While small molecules are released from 
unilamellar liposomes in minutes, they are retained in vesosomes from hours to 
days, even though the liposomes and vesosomes have the same bilayer 
composition and size. Vesosomes are formed by adding ethanol to a variety of 
saturated phospholipids. At temperatures below the gel-liquid crystalline 
transition, Tm, the inter digitated lipid-ethanol sheets are rigid and flat; when the 
temperature is raised above Tm, the sheets become flexible and close on 
themselves and the surrounding solution to form closed compartments. 
SUBTILOSOMES
11
 
Subtilosomes are prepared from phospholipids isolated from Bacillus 
subtilis. They are novel potential carrier system used in drug delivery. Cardiolipin 
and phosphatidyl glycerol are abundant in B. subtilis. 
ESCHERIOSOMES
11
 
These are lipoidal vesicles, prepared from polar lipids extracted from 
Escherichia coli. Majorly phosphatidyl ethanolamine, cardiolipin, and 
phosphatidyl glycerol are classes of phospholipid, present in E. coli. 
Escheriosomes encapsulated antigen elicit strong humoral immune response in 
immunized animals, in general, escheriosomes are considered as potential 
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candidate vaccine carrier system capable of eliciting both cell-mediated as well as 
humoral immune responses.  
MARINOSOMES
11 
Marinosomes are liposomes based on a natural marine lipid extract 
containing high ratio of polyunsaturated fatty acids (PUFA) like eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA), which are not present in normal skin 
epidermis. They are metabolized by skin epidermal enzymes into anti-inflammatory 
and anti-proliferative metabolites that are beneficial in treating inflammatory skin 
disorders. However, the preventing effect of marinosomes was highly dependent on 
the lipid concentration used and the liposome mean diameter. Active and passive 
loading of drug, as well as complex structural rearrangements directly depends on 
transmembrane pH gradient. All these results allowed considering marinosomes as 
potential candidates for cosmeceutical and oral PUFA supplements in view of the 
prevention and treatment of deficiencies. 
ASPASOMES
11 
Vesicles prepared with amphiphiles having antioxidant property may have 
potential applications towards disorders implicated with reactive oxygen species. 
Ascorbyl palmitate (ASP) was explored as bilayered vesicle forming material. It 
forms vesicles in combination with cholesterol and a negatively charged lipid 
(dicetyl phosphate). Aspasome rendered much better antioxidant activity. 
ARCHAEOSOME
11 
Archaeosome constitute a novel family of liposome made with one or 
more of the fully saturated bipolar tetra ether lipids, which exerts a higher stability 
in comparison with conventional lipids to several conditions such as high 
temperature, alkaline or acidic pH, and presence of phospholipases, bile salts and 
serum media. They are nano-sized vesicles prepared from total polar lipids either 
extracted from the selected genera and species of the Archaea domain or synthetic 
archaeal lipids. Incorporation of polyethylene glycol and coenzyme Q10 into 
archaeosomes has been found to alter the tissue distribution profiles of 
intravenously administered vesicles. Also, intravenous and oral delivery of 
nanometric-sized archaeosomes to an animal model was well tolerated with no 
apparent toxicity. 
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DISCOMES
 9 
Niosomes are solubilised with Sollulan C24 (polyoxy ethylene cetyl ether 
class) in order to effect vesicle to discome transition. Discomes are relatively large 
in size (12- 60 micrometer) and are capable of entrapping high quantities of water- 
soluble solutes. They were found to release the contents following biphasic profile 
particularly in the case where the drug was loaded using pH gradient technique. 
The prepared system could produce or sustain a suitable activity profile upon 
administration. The discomes were found to be promising and of potential for 
controlled ocular administration of water- soluble drugs. 
BILOSOMES 
5 
Bilosomes are the novel innovative drug delivery carriers consist of 
deoxycholic acid incorporated into the membrane of niosomes. As conventional 
vesicles (liposomes and niosomes) can cause dissolution and undergo enzymatic 
degradation in gastro intestinal tract but incorporation of bile salts (commonly 
used penetration enhancers) in niosomal formulation could stabilize the membrane 
against the detrimental effects of bile acids in GI tract. These bile salt stabilized 
vesicles are known as bilosomes. These are highly biocompatible and have been 
found to improve the therapeutic efficacy of drugs due to their stability in gastro 
intestinal tract. Bilosomes have been found to increase the bioavailability of drugs 
as they can readily absorbed through small intestine to the portal circulation 
(hepatocirculation). Through this circulation they approach to liver and release the 
drug, so found to be an effective tool in drug targeting to liver. 
AQUASOMES
 5 
Molecules are adsorbed by copolymerization, diffusion or adsorption with 
or without modification. The solid core provides the structural stability, while the 
carbohydrate coating protects against dehydration and stabilizes the biochemically 
active molecules. Aquasomes are spherical 60- 300nm size particles called 
“bodies of water”. Due to their size and structural stability, these avoid clearance 
by reticuloendothelial system and degradation by other environmental changes. 
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HEMOSOMES
11 
New artificial oxygen transporting systems engineered by immobilizing 
haemoglobin with polymerisable phospholipids, capable of prolonged activity in the 
circulation are of special interest. Natural hemoglobin was incorporated into 
liposomes of different composition (so- called hemosome). It was shown that the 
maximal quantity of hemoglobin obtained from lysed erythrocytes incorporates into 
negatively charged liposomes. Stabilized hemosomes bind oxygen in the same way as 
human blood hemolysates. 
 
APPROACHES FOR IMPROVEMENT OF VESICULAR 
SYSTEM
4 
Pro-vesicular Drug Delivery 
 Pro-vesicular drug delivery developed to overcome the stability problems 
associated with vesicular drug delivery systems composed of water soluble porous 
powder as a carrier drug is dissolved in organic solvent to produce free-flowing 
granular product. It can avoid many of the problems associated with aqueous 
vesicular dispersions. 
Types of pro vesicular drug delivery systems 
 Proliposomes, 
 Proniosomes 
PROLIPOSOMES 
Comparision between liposomes and proliposomes. Liposomes-Unilamellar or 
multilamellar spheroid structures composed of lipid molecules, often phospholipids. 
They show controlled release and increased solubility. But have tendency to aggregate 
or fuse, susceptible to hydrolysis or oxidation. Proliposomes- an alternative forms to 
conventional liposomal formulation Composed of water soluble porous powder as a 
carrier, phospholipids and drugs dissolved in organic solvent. Lipid and drug are 
coated on to a soluble carrier to form free-flowing granular material. Show controlled 
release, better stability, ease of handling and increased solubility. 
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PRONIOSOMES
 24,26 
Proniosomes are non ionic surfactant-coated carrier, which when needed, are 
rehydrated by brief agitation in  water. These are considered superior drug delivery 
system because of their low cost, greater stability, non-toxicity, biocompatible, 
biodegradable and non-immunogenic, as it is nonionic in nature. 
ADVANTAGES OF PRONIOSOMES 
            Liposomes and niosomes are well known drug/ cosmetic delivery systems. But 
these delivery systems have been reported to have many disadvantages in terms of 
preparation, storage, sterilization, etc. the disadvantages of liposomes and niosomes 
are given below, which can be overcome by Proniosomes. 
  Liposomes and niosomes are dispersed aqueous system and have a 
problem of degradation by hydrolysis or degradation. 
  Liposomes and niosomes require special storage and handling. 
  Sedimentation, Aggregation or fusion on storage is usually seen. 
  In liposomes, purity of natural phospholipids is also variable. 
  Difficulty in sterilization, transportation, distribution, storage uniformity 
of dose and scale up. 
  Use of unacceptable solvents. 
  Incomplete hydration of the lipid / surfactant film on the walls during 
hydration process. 
Disadvantages of Niosomes 
 Physical instability 
 Aggregation 
 Fusion 
 Leaking of entrapped drug 
 Hydrolysis of encapsulated drugs which limiting the shelf life of the 
dispersion. 
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Table 1 - Commonly used materials for Proniosome preparation 
 
 
STRUCTURE OF NIOSOMES 
 
Figure:2 structure of niosomes 
These are microscopic lamellar structure. They combine a non-ionic surfactant 
of the alkyl or dialkyl polyglycerol ether class of cholesterol followed by hydration in 
the aqueous media. The surfactant molecule direct themselves such that the 
S.No           Class        Examples         Use 
1. Surfactants Span 20,40,60,80,85,Tween 
20,40,60,80. 
To increase drug flux 
rate cross the skin. 
2. Cholesterol Cholesterol To prevent the 
leakage of drug 
formulation. 
3. Lecithin Lecithin Penetration enhancer. 
4. Maltodextrin Maltodextrin Provides flexibility in 
surfactant and other 
component ratio. 
5. Sorbitol Sorbitol Alters the drug 
distribution. 
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hydrophilic end of the non- ionic surfactant orient outward, while the hydrophobic 
end are in the opposite direction to form the bilayer. Like liposomes proniosomes are 
also made of bilayer. In proniosomes this bilayer are made up of non-ionic surface 
active agent. On the basis of method of preparation proniosomes are unilamellar or 
multilamellar. 
 
 
 
 
Figure:3 Formation of niosomes from proniosomes 
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TYPES OF PRONIOSOMES 
13,17,24
 
1) Dry granular proniosomes 
 Sorbital based proniosomes 
 Maltodextrin based proniosomes 
2) Liquid crystalline proniosomes.
 
 
Sorbitol based proniosomes 
Sorbital based proniosomes are is a dry formulation which consist 
proniosomes as carrier, which is further coated with non-ionic surfactant and is used 
as niosomes within a minute by addition of hot water followed by agitation. This are 
usually made by spraying the surfactant mixture prepared in organic solvent on to the 
sorbitol powder then evaporating the solvent. Since the sorbitol carrier is soluble in 
organic solvent, the process is required to be repeated till the desired surfactant 
coating has been achieved. In sorbitol based proniosomes size distribution is uniform. 
It is useful in case where the active ingredient is susceptible to hydrolysis. The 
residual sorbitol decreases entrapment efficiency to less than one half of that observed 
with sorbitol. This necessiate reduction in proportion of carrier in final niosome 
suspension. The difficulty lies in testing of sorbitol particles because sorbitol is 
soluble in chloroform and other organic solvent. Its prepared by slow spraying 
method. 
Maltodextrin based proniosomes 
 It is prepared by fast slurry method. Time required to produce proniosomes by 
slurry method is independent of the ratio of surfactant solution to carry out. 
Proniosomes of high surface to carrier ratio can be carried out. Proniosomes of high 
surface to carrier ratio can be prepared. The method of obtaining niosomes from such 
a proniosomes for the drug delivery is very simple. An analogue process with Sorbital 
results in a solid, surfactant/sorbitol cake. Since maltodextrin morphology is 
preserved, hollow blown maltodextrin particles can be used for significant gain in 
surface area. The higher surface area results in thinner surface coating, which makes 
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the rehydration process efficient. This preparation has potential of application in 
delivering of hydrophobic and amphiphilic drug molecule. 
Liquid crystalline proniosomes 
            When the surfactant molecule is kept in contact with water, there are three 
ways through which lipophilic chains of surfactant can be transformed into a 
disordered, liquid state called lyotrpoic liquid crystalline state(neat phase). These 
three ways are increasing the Kraft temperature (Tc), addition of solvent which 
dissolve lipids, and use of both temperature and solvent. Neat phase also known as 
lamellar phase contains bilayer arranged in a sheet over one another within 
intervening aqueous layer. This type of structure gives typical x-ray diffraction and 
thread like birefrigerant structure under polarized microscope. The lamellar crystalline 
phase is converted into niosomes at higher concentration. The liquid crystalline 
proniosomes and proniosomal gel acts as reservoir for transdermal drug delivery. 
 
Liquid crystalline proniosomes display a number of advantages: 
 Stability 
 High entrapment efficiency 
 As a penetration enhancer 
 Easy to scale up as no lengthy process is involved; moreover it avoids the use 
of pharmaceutically unacceptable additives. 
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COMPONENTS OF PRONIOSOMES
24 
The essential components of the delivery system are as follows 
Surfactants 
Surfactants are the surface active agent usually organic compounds that are 
amphiphilic in nature (having both hydrophobic and hydrophilic groups). They have 
variety of functions including acting as solubilizers, wetting agents, emulsifiers and 
permeability enhancer. The most common non-ionic amphiphiles used for vesicle 
formation are alkyl ethers, alkyl esters, alkyl amides and esters of fatty acids. 
Selection of surfactant should be done on the basis of HLB value. As Hydrophilic 
Lipophilic Balance (HLB) is a good indicator of the vesicle forming ability of any 
surfactant. The water soluble detergent polysorbate 20 also forms niosomes in the 
presence of cholesterol. This is despite the fact that the HLB number of this 
compound is 16.7 Degree of entrapment is affected by the HLB of a surfactant. 
Transition temperature of surfactants also affects the entrapment of drug in vesicles. 
Spans with highest phase transition temperature provide the highest entrapment for 
the drug and vice versa. Span 40 and Span 60 produces vesicles of larger size with 
higher entrapment of drug. The drug leaching from the vesicles is reduced due to high 
phase transition temperature and low permeability. High HLB value of Span 40 and 
60 results reduction in surface free energy which allows forming vesicles of larger 
size hence large area exposed to the dissolution medium and skin. No significant 
difference is observed in the skin permeation profile of formulation containing Span 
60 and Span 40surfactant, due to their higher phase transition temperature that is 
responsible for their lower permeability. The encapsulation efficiency of Tween is 
relatively low as compared to Span.  
The geometry of vesicle to be formed from surfactants is affected by its 
structure, which is related to critical packing parameters. On the basis of critical 
packing parameters of Surfactants can predicate geometry of vesicle to be formed. 
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Critical packing parameters can be defined using following equation, 
                       CPP =                    V 
                                                Lc X Ao 
CPP   =   0.5 – 1 spherical vesicles form 
CPP =   1 inverted vesicles form 
V     =   Hydrophobic group volume 
Lc   =    the critical hydrophobic group length,, 
Ao  = the area of hydrophilic head group. 
 
Table2: List of surfactants used in proniosomes formulation 
 
Non-ionic amphiphiles Examples 
Alkyl ethers and alkyl glyceryl Ethers Polyoxyethylene 4 lauryl ether (Brij30) 
Polyoxyethylene cetyl ethers Brij 52, 56, 58 
Polyoxyethylene stearyl ethers Brij 72, 76 
Sorbitan fatty acid esters Span 20, 40, 60, 80 
Polyoxyethylene sorbitan fatty acid esters Tween 20, 40, 60, 80 
Carrier material 
The carrier when used in the proniosomes preparation permits the flexibility in 
the ratio of surfactant and other components that incorporated. In addition to this, it 
increases the surface  area and hence efficient loading. The carriers should be safe and 
non-toxic, free flowing, poor  solubility in the loaded mixture solution and good water 
solubility for ease of hydration. Commonly used carriers are listed, they are sorbitol, 
mannitol, Glucose, Lactose, Sucrose stereate. Another polysaccharide that can be used 
as carrier is maltodextrin .It has minimal solubility in organic solvent. Thus it is 
possible to coat maltodextrin. It forms particles by simply adding surfactant in organic 
solvent. The use of maltodextrin as carrier in Proniosomes preparation permitted 
flexibility in the ratio of surfactant and other components  which can be incorporated. 
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Membrane stabilizers 
Cholesterol and lecithin are mainly used as membrane stabilizer. Steroids are 
important components of cell membrane and their presence in membrane and their 
presence in membrane brings about significance changes with regard to bilayer 
stability, fluidity and permeability. Cholesterol is a naturally occurring steroid used as 
membrane additive. It prevents aggregation by the inclusion of molecules that 
stabilize the system against the formation of aggregate by repulsive steric or 
electrostatic effects. It leads transition from the gel state to liquid phase in niosomes 
system. Phosphatidylcholine is a major component of lecithin. It has low solubility in 
water and can form liposomes, bilayer sheets, micelles or lamellar structures 
depending on hydration and temperature. Depending upon the source from which they 
are obtained they are as named as egg lecithin and soya lecithin. It acts as stabilizing 
as well as penetration enhancer. It is found those vesicles composed of soyalecithin 
are of larger size than vesicle composed of egg lecithin probably due to the difference 
in the intrinsic composition. Cholesterol increases or decreases the percentage 
encapsulation efficiency depending on either the type of the surfactant or its 
concentration within the formula. Cholesterol along with the addition of surfactant 
forms homogenous noisome dispersion rather than only a surfactant which forms a 
gel. Cholesterol is thus usually included in a 1:1 molar ratio in most formulations as it 
is known to abolish the gel to liquid phase transition of niosomes systems resulting in 
niosomes that are less leaky. The amount of cholesterol to be added depends on the 
HLB value of the surfactants. As the HLB value increases above 10 it is necessary to 
increase the minimum amount of cholesterol to be added in order to compensate for 
the larger head groups. It was found that above a certain of cholesterol, entrapment 
efficiency decreased possibly due to a decrease in volume diameter. 
Solvent and aqueous phase 
Alcohol used in Proniosomes has a great effect on vesicle size and drug 
permeation rate. Vesicles formed from different alcohols are of different size and they 
follow the order: Ethanol > Propanol > Butanol > Isopropanol. Ethanol has greater 
solubility in water hence leads to formation of highest size of vesicles instead of 
Isopropanol which forms smallest size of vesicle due to branched chain present. 
Phosphate buffer pH 7.4, 0.1% glycerol, hot water is used as aqueous phase in 
preparation of proniosomes. 
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Drug 
The drug selection criteria could be based on the following assumptions. 
 Low aqueous solubility of drugs. 
 High dosage frequency of drugs. 
 Short half-life. 
 Controlled drug delivery suitable drugs. 
 Higher adverse drug reaction drugs. 
Hydration medium 
Phosphate buffer having various pH  are most widely used hydration medium 
for preparationof proniosomes derived niosomes. The solubility of drug being 
encapsulated determines the actual pH of hydration medium. The temperature of 
hydration also plays an important role in governing the self-assembly of non-ionic 
surfactant into vesicles and affects their shape and size. In case of proniosomal gel 
preparation, the hydrating temperature used to make niosomes should usually be 
above the gel to liquid phase transition temperature of the system. 
Nature of encapsulated drug 
The main factor in the consideration is the influence of an amphiphilic drug on 
vesicle formation. When drug was encapsulated in niosomes, aggregation occurred 
and was overcome by the addition of a steric stabilizer. When more drugs is added the 
increase in its encapsulation could be the result of saturation of the medium. This 
suggests that the solubility of certain poorly soluble drugs can be increased by 
formulation in niosomes but only up to a certain limit above which drug precipitation 
will occur. Increase in drug concentration showed an increase in both percentage 
encapsulation efficiency and the amount of drug encapsulated per mole total lipids 
upon hydration and formation of niosomes. 
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Formation of niosomes from proniosomes 
           The niosomes can be prepared from the proniosomes (as shown in figure 2) by 
adding the aqueous phase with the drug to the proniosomes with brief agitation at a 
temperature greater than the mean transition phase temperature of the surfactant. 
T > Tm 
Where, 
T = Temperature 
Tm = Mean phase transition temperature. 
 
Figure 4: Formation of niosomes from proniosomes 
 
Mechanism of Action 
           The exact mechanism of penetration of drug in the vesicles through the skin are 
not yet explored, but the penetration will depends on the nature and type of the drug 
used, vesicles formed and hydration temperature for the conversion of proniosomes to 
Niosomes. The lipids used in the preparation of proniosomes, act as carrier that will 
form depot at the site of action and hence sustains the action. The rate-limiting step in 
the penetration of drug through the transdermal drug delivery is the lipid (ceramides) 
part of stratum corneum, which packed tightly as bilayer by hydrogen bonding. The 
hydrogen bonding will strengthen and stabilize the lipid bilayer and as a result will 
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impart the barrier property of stratum corneum .Proniosomes will hydrate to niosomes 
when applied to skin. On to the skin surface, the niosomes formed adsorbs fuses and 
loosens the ceramides by competitively breaking the hydrogen bond network leading 
to high thermodynamic activity at the interface. This will increase the increases the 
concentration gradient and hence increases the diffusion pressure for the driving of 
drug through the stratum corneum. 
 
METHOD OF PREPARATION OF PRONIOSOMES
13,17,24 
 
  Proniosomes are prepared by following methods. 
 a.Slurry Method 
 b.Coacervation phase separation method 
 c.Spray coating method. 
SLURRY METHOD 
Proniosomes can be prepared by addition of the carrier and the entire surfactant 
solution in a round bottomed flask which is fitted to rotary flash evaporator and 
vacuum was applied to form a dry and free flowing powder. Finally, the formulation 
should be stored in tightly closed container under refrigeration in light. The time 
required for proniosomes production is independent of the ratio of surfactant solution 
to carrier material and appears to be stable. The proniosomal powder formed is 
collected and sealed in containers and stored at 4°C. 
Proniosomes are prepared by developed slurry method using Maltodextrin as a 
carrier. The required volume of surfactant and cholesterol stock solution per gram of 
carrier and drug should be dissolved in the solvent in 100 ml round bottom flask 
containing the carrier (Maltodextrin). Additional chloroform can be added to form 
slurry in case of lower surfactant loading. The flask has to be attached to a rotary flash 
evaporator to evaporator solvent at 50-60 rpm at a temperature of45-2
  
C and a 
reduced pressure of 600mm Hg until the mass in the flask had become container 
under refrigeration in light. 
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Advantages of slurry method 
          a) Maltodextrin like polysaccharide which is easily soluble in water and 
it is used as carrier material in formulation; they were easily coated by simply 
adding surfactant in organic solvent to dry maltodextrin. 
          b) Due to uniform coating on the carrier it protect the active ingredient 
and the surfactants from hydrolysis and oxidation. 
        c) The higher surface area results in thinner surfactant coating which 
makes the rehydration process efficient. 
Disadvantages of slurry method 
a) Method is time consuming and involves specialised equipment with 
vacuum. 
b) The thin film approach allows only for a predetermined lot sizes so 
material often wasted, so small quantities and small dose batch can be 
tedious one. 
 
 COACERVATION PHASE SEPARATION METHOD 
Proniosomal gels can be prepared by this method which comprises of 
surfactant, lipid and drug in a wide mouthed glass vial along with small 
amount of alcohol in it. The mixture is warmed over water bath at 60-70 C 
for 5min until the surfactant mixture is dissolved completely. Then the little 
aqueous phase is added to the above vial and warmed still a clear solution is 
formed which is then converted into proniosomal gel on cooling.  After 
hydration of proniosomes they are converted to uniformly sized niosomes. 
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Figure 5: Diagrammatic representation of preparation of proniosomal gel 
Advantages of this method 
a) Method is simple and without time consumable so it does required 
any specialized equipment. 
b) Specially adopted for gel preparation 
c) Small quantities or small dose formulation can be prepared on lab 
scale. 
SLOW SPRAY COATING METHOD 
In this method, the surfactant is added to an organic solvent and 
sprayed onto carrier. Then the solvent is evaporated. This process is repeated 
until the desired surfactant loading is achieved, because the carrier is soluble 
in the organic solvent. As the carrier dissolved, hydration of this coating 
allows the formation of multilamellar vesicles. These niosomes have uniform 
size distribution and similar to those produced by conventional methods. A 
100 ml round bottom flask containing desired amount of carrier can be 
attached to rotary flash evaporator. A mixture of surfactant and cholesterol 
should be prepared and introduced into round bottom flask on rotary 
evaporator by sequential spraying of aliquot sonto carrier‟s surface. The 
evaporator has to be evacuated and rotating flask can be rotated in water bath 
under vacuum at 65-70
 o
 C for 15-20 min. This process has to be prepared 
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until all of the surfactant solution had been applied. The evaporation should be 
continued until the powder becomes completely dry.  
Advantages 
It‟s a simple method suitable for hydrophobic drug without concerns of 
instability or susceptibility of active pharmaceutical ingredient to hydrolysis. 
Disadvantages 
1. Method is time consuming and involves specialized equipment with 
vacuum. 
2. The thin film approach allows only for a predetermined lot sizes so 
material        often wasted so minute quantities or small dose batch can be 
tedious one. 
FACTORS AFFECTING ENTRAPMENT EFFICIENCY AND 
SIZE OF  VESICLES
 2,11 
Entrapment efficiency is the measure of solute retention. High entrapment      
efficiency means a less time and less effort needed to remove the unentrapped drug. 
Entrapment efficiency and vesicular size are important parameters to predict the 
stability of the dispersion. If the prepared formulation remains the unchanged 
vesicular size and entrapment efficiency even after storage, hence the formulation 
considered stable. 
 NON-IONIC SURFACTANTS 
The non-ionic surfactant used act as vesicle forming agent, the amount and its 
nature will affect the entrapment and vesicular size. 
A. Nature of non-ionic surfactant 
          The entrapment efficiency and vesicular size depends upon the HLB value, 
chemical nature and phase transition temperature. The surfactant with high or low 
HLB value has high entrapment efficiency with some approaching 100%. In addition 
to HLB, the chemical structure of the surfactant i.e., the alkyl chain length will also 
affect the entrapment, which is directly proportional to the phase transition 
temperature. The higher the alkyl chain higher will be the entrapment efficiency; as it 
is having high phase transition temperature thereby it is more likely to form orderly 
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gel form and hence less leaky. While surfactant with lower phase transition 
temperature are likely to form less orderly liquid. The increase in leakiness means it 
has less entrapment efficiency. This is evident from the report that, Sorbitan 
monooleate (span 20, span 80) and Stearate Sucrose Ester shows higher entrapment 
efficiency, as their alkyl chain is longer thereby higher phase transition temperature. 
Whereas, Tween 20 and 80 have higher HLB, value and hence showed lower 
entrapment compared to span series. While Tween 80 has comparatively higher 
efficiency than Tween 20, because of higher phase transition temperature due to 
longer alkyl chain. 
B. Amount of surfactant 
              The increase in surfactant amount will increase the entrapment efficiency 
because the surfactant being the vesicle forming agent. 
Table 3: Physical Properties of Non-ionic surfactants 
S.No.        Surfactant Synonyms Properties 
1. Sorbitan 
Monolaurate 
Span 20, Sorbitan 
Monodecanoate 
Tc : 16ºC 
Density: 1.032 g/mL at 25°C 
(lit.) 
Flash point:>230°F 
HLB value: 8.6 
2. Sorbitan 
Monopalmitate 
Span 40 Tc : 42ºC 
Flash point:113ºC 
Melting point: 46-47ºC 
HLB value: 6.7 
3. Sorbitan 
monostearate 
Span 60, Sorbitan 
monooctadecanoate 
Tc : 53ºC 
Flash point: >110ºC 
Melting point: 54-57ºC 
HLB value: 4.7 
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4. Sorbitan 
Monooleate 
Span 80, Sorbitan 
(Z)-mono-9- 
octadecenoate 
Tc : -12ºC 
Flash point: >110ºC 
Density: 0.986 
HLB value:4.3 
5. Polyoxyethylene 
(20)sorbitan 
Monolaurate 
Tween 20 Density: 1.106 
Aq.solubility: 100 g/L 
Boiling point: 100 ºC  
HLB value: 16.7 
6. Polyoxyethylene 
(20)sorbitan 
monopalmitate 
Tween 40 Density: 1.05 
Aq.solubility: 100 g/L 
Boiling point: 0.1 ºC 
 HLB value: 15.6 
7. Polyoxyethylene 
(20)sorbitan 
Monostearate 
Tween 60 Density: 1.081 
Aq.solubility: 100 g/L 
HLB value: 14.9 
8. Polyoxyethylene 
(20)sorbitan 
Monooleate 
Tween 80 Density: 1.064 
Aq.solubility: 5-10g/100 mL 
at 23 ºC 
Flash point: >110 ºC 
HLB value: 15.0 
 
CHOLESTEROL 
              Cholesterol that acts as cementing agent, when its concentration is increased 
which will considerably decrease the entrapment efficiency. It will retard the afflux 
profile of entrapped drug. The reason behind decrease in the entrapment efficiency 
due to increase in cholesterol is that with higher amounts of cholesterol may compete 
with the drug for packing space within the bilayer, hence excluding the drug as the 
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amphiphiles assemble into the vesicles. However, the effect of cholesterol will vary 
the entrapment efficiency according to the surfactant used. In span series the 
entrapment efficiency was increased with cholesterol to some extent, further increase 
lead to the decreased entrapment efficiency. This is explained to be due to the 
following fact that a small increase in cholesterol increases bilayer hydrophobicity 
and stability, thus the permeability is decreased, as it efficiently traps the drug in the 
bilayer as vesicles are formed. However, the cholesterol may compete with the drug 
as the concentration is beyond certain limit. 
CHARACTERIZATION OF PRONIOSOMES
17,19 
 
Table 4: Shows methods for the characterization of proniosomes 
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  Provesicles are characterized for vesicle size and morphology, entrapment 
efficiency, In vitro release and permeation studies, In vivo studies, stability studies 
etc. 
Vesicle size and morphology -Vesicle morphology 
           It involves the measurement of size and shape. The size of the vesicles can be 
measured by light scattering method and optical microscopy in two conditions i.e: 
with agitation and without agitation. Hydration without agitation results in largest 
vesicle size. Surface morphology means roundness, smoothness and formation of 
aggregation; it can be studied by scanning electron microscopy and transmission 
electron microscopy. 
Optical microscopy 
              In optical microscopy, small amounts of the formed niosomes are spread on a 
glass slide and examined for the vesicles structure and the presence of insoluble drug 
crystals using ordinary light microscope with varied magnification power 100x. 
Scanning electron microscopy 
             Particle size of proniosomes is very important characteristic. The surface 
morphology (roundness, smoothness, and formation of aggregates) and the size 
distribution of proniosomes were studied by Scanning Electron Microscopy (SEM). 
For scanning electron microscopy, the niosomes are mounted on an aluminum stub 
using double sided adhesive carbon tape. Then the vesicles are sputter coated with 
gold palladium (Au/Pd) using a vaccum evaporator and examined using a Scanning 
electron microscopy equipped with a digital camera at 25kV accelerating voltage. 
Transmission electron microscopy 
             The morphology of hydrated niosome dispersion prepared from proniosome 
was also determined using transmission electron microscopy (TEM). The noisome 
dispersion is applied to a carboncoated 300 mesh copper grid and left to allow some 
of the niosomes to adhere to the carbon  substrate. The remaining dispersion is 
removed by absorbing the drop with the corner of a piece of filter paper. Then drop of 
aqueous solution of uranyl acetate is applied. The remaining solution is removed by 
absorbing the liquid with the tip of a piece of filter paper and the sample is air dried 
and observed under transmission electron microscope. 
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Entrapment  Efficiency 
Various methods can be used to evaluate the loading capacity of proniosomal systems 
such as dialysis method, gel filtration and centrifugation method. In dialysis method, 
amount of entrapped drug can be obtained by subtracting the amount of unentrapped 
drug from total drug incorporated.  
 
 
 
In -vitro release and permeation studies 
In- vitro release and skin permeation studies for proniosomes were determined 
by different techniques like franz diffusion cell, dialysis tubing and reverse dialysis. 
In case of dialysis, the prewashed dialysis tubing is used which can be hermatically 
sealed, the proniosomes are placed in it and then dialysed against a suitable 
dissolution medium at a room temperature. The samples are withdrawn from the 
medium at suitable interval, centrifuged and analysed spectrophotometrically (UV, 
HPLC). 
Stability studies 
Stability studies are carried out by storing the proniosomes at various 
temperature conditions like refrigeration, room temperature and elevated temperature 
according to ICH guidelines. Drug content and variation in the average vesicles 
diameter is periodically monitored. According to ICH guidelines the stability studies 
for dry proniosomes powder should be studied for accelerated stability at 75% relative 
humidity as per international climate zones and climate conditions. 
 
 
 
 
 
Entrapment efficiency(EE)  = Amount of drug entrapped/total amount of drug×100 
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CLINICAL APPLICATIONS OF PRONIOSOMES
17,19 
 
              Approaches to stabilize niosomal drug delivery system without affecting its 
properties of merits have resulted in the development of the promising drug carrier, 
proniosomes. Proniosomes is dry formulation using suitable carrier coated with non 
ionic surfactants and can be converted into niosomes immediately before use by 
hydration. These proniosome-derived niosomes are as good as or even better than 
conventional niosomes. The application of proniosomal technology is widely varied 
and can be used to treat a number of diseases. The following are the few uses of 
proniosomes which are either proven or under research. 
1. Anti-neoplastic Treatment : 
             Most antineoplastic drugs cause severe side effects. Niosomes can alter the   
metabolism; prolong circulation and half life of the drug, thus decreasing the side 
effects of the drugs. Niosomal entrapment of Doxorubicin and Methotrexate  (in two 
separate studies) showed beneficial effects over the unentrapped drugs, such as 
decreased rate of proliferation of the tumor and higher plasma levels accompanied by 
slower elimination.  
2. Leishmaniasis : 
              Leishmaniasis is a disease in which a parasite of the genus Leishmania 
invades the cells of the liver and spleen. Commonly prescribed drugs for the treatment 
are derivatives of antimony (antimonials), which in higher concentrations can cause 
cardiac, liver and kidney damage. Use of pronoisome in tests conducted showed that 
it was possible to administer higher levels of the drug without the triggering of the 
side effects, and thus allowed greater efficacy in treatment.  
3.Delivery of Peptide Drugs : 
            Oral peptide drug delivery has long been faced with a challenge of bypassing 
the enzymes which would breakdown the peptide. Use of niosomes to successfully 
protect the peptides from gastrointestinal peptide breakdown is being investigated. In 
an in-vitro study conducted by Yoshida et al, oral delivery of a vasopressin derivative 
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entrapped in niosomes showed that entrapment of the drug significantly increased the 
stability of the peptide.  
4. Uses in Studying Immune Response: 
               Proniosomes are used in studying immune response due to their 
immunological selectivity, low toxicity and greater stability. Niosomes are being used 
to study the nature of the immune response provoked by antigens.  
5. Proniosomes as Carriers for Haemoglobin : 
Niosomes can be used as carriers for haemoglobin within the blood. The 
niosomal vesicle is permeable to oxygen and hence can act as a carrier for 
hemoglobin in anemic patients. 
6. Proniosomes used in Cardiac Disorders: 
Proniosomal carrier system for captopril for the treatment of hypertension that 
is capable of efficiently delivering entrapped drug over an extended period of time. 
The potential of proniosomes as a transdermal drug delivery system for captopril was 
investigated by encapsulating the drug in various formulations of proniosomal gel 
composed of various ratios of sorbitan fatty acidesters, cholesterol, lecithin prepared 
by coacervation-phase separation method. The formulated systems were characterized 
in-vitro for size, vesicle count, drug entrapment, drug release profiles and vesicular 
stability at different storage conditions. Stability studies for proniosomal gel were 
carried out for 4 weeks.  The current study was to investigate the feasibility of 
proniosomes as transdermal drug delivery system for losartan potassium.  
7. Sustained Release: 
The role of liver as a depot for methotrexate after niosomes are taken up by 
the liver cells. Sustained release action of niosomes can be applied to drugs with low 
therapeutic index and low water solubility since those could be maintained in the 
circulation via niosomal encapsulation.  
8. Localized Drug Action: 
          Drug delivery through niosomes is one of the approaches to achieve localized 
drug action, since their size and low penetrability through epithelium and connective 
tissue keeps the drug localized at the site of administration. Localized drug action 
results in enhancement of efficacy of potency of the drug and at the same time 
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reduces its systemictoxic effects e.g. Antimonials encapsulated within niosome are 
taken up by mononuclear cells resulting in localization of drug, increase in potency 
and hence decrease both in dose and toxicity. The evaluation of niosomal drug 
delivery technology is still at an infancy stage, but this type of drug delivery system 
has shown promise in cancer chemotherapy and antileishmanial therapy.  
9. Hormonal Therapy: 
          A proniosome based transdermal drug delivery system of levonorgestrel (LN) 
was developed and extensively characterized both in-vitro and in-vivo. The 
proniosomal structure was liquid crystalline compact niosomes hybrid which could be 
converted into niosomes upon hydration. The system was evaluated in-vitro for drug 
loading, rate of hydration (spontaneity), vesicle size, polydispersity, entrapment 
efficiency and drug diffusion across rat skin. The effect of composition of 
formulation, amount of drug, type of Spans, alcohols and sonication time on 
transdermal permeation profile was observed. The stability studies were performed at 
4°C and at room temperature. The biological assay for progestational activity included 
endometrial assay and inhibition with the formation of corpora lutea. The study 
demonstrated the utility of proniosomal transdermal patch bearing levonorgestrel for 
effective contraception.  
10. Cosmetics formulation:  
Large number of cosmetic preparations available in the market is utilizing niosomes 
and liposomes as a carrier for delivery of actives. Liposomes were prepared using 
unacceptable organic solvents, whose traces in the final preparation can cause harm to 
the skin. It is proved that proniosomes are as effective as noisome and liposomes, but 
their preparation, handling, storage and transportation make them superior over 
others. The therapeutic agents which can be utilized for incorporation into 
proniosomal carrier systems include, moisturizing, nutritional, anti wrinkle, anti-
ageing, cleansing, sunscreen particles, etc. 
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11. NSAID  Application: 
              Ketorolac trimethamine (KT) is a nonsteroidal agent with potent analgesic 
and moderate anti-inflammatory activity. The drug is currently administered 
intramuscularly and orally in divided multiple doses for short-term management of 
postoperative pain (30 mg q.i.d. by IM injection and 10 mg q.i.d. as oral tablets). This 
frequent dosing, which results in unacceptable patient compliance, is required due to 
the short half-life of the drug (4–6 h). Therefore, an alternative noninvasive mode of 
delivery of the drug is needed. Transdermal delivery certainly appears to be an 
attractive route of administration to maintain the drug blood levels of KT for an 
extended period of time . Piroxicam, a non-steroidal anti-inflammatory drug 
(NSAID), are used in the treatment of dysmenorrheal various acute and chronic 
musculoskeletal disorders like rheumatoid arthritis, osteoarthritis etc., and also as 
potent analgesics . However, the use of piroxicam has been associated with a number 
of gastrointestinal disorders. Dermal delivery is an alternative route, butrequires a 
formulation which ensures the deep skin penetration. Aceclofenac In the present study 
the slurry method was used for the preparation and optimization study of aceclofenac, 
as this method is simple and easy to scale up. Aceclofenac is a poorly water soluble, 
non-steroidal anti-inflammatory drug which acts specifically on inflammatory sites 
and thereby decreases the inflammation. It is highly effective as an anti-inflammatory 
drug for various inflammatory conditions like rheumatoid arthritis, osteoarthritisand 
ankylosing spondylitis.  
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2 REVIEW LITRATURE 
 
1. Amit kumar et al.
27
  developed maltodextrin based stavudine proniosomes drug 
delivery systems were developed by using nonionic surfactant:cholesterol at different 
concentrations. All the prepared formulations are subjected into physicochemical 
evaluations. These results the entrapment efficiency of niosomes prepared from 
proniosomes at varied concentration of surfactants:cholesterol keeping stavudine 
concentration constant. The percentage entrapment efficiency range of 56.22 ± 0.15 to 
94.45 ±0.16.Higher surfactant concentration viz ,Span 60, Span 40 shows higher 
entrapment efficiency which might be due to the high fluidity of the vesicles. The 
larger vesicle size may also contribute to the higher entrapment efficiency. 
2. Mohamed Nasr et al.
28
 developed Celecoxib proniosomes and evaluate the 
influence of proniosomal formulation on the oral bioavailability of the drug in human 
volunteers. Proniosomes were prepared by sequential spraying method .which 
consisted of cholesterol, Span 60 and dicetyl phosphate in amolar ratio of 1:1:0.1.The 
average entrapment percent of Celecoxib proniosomes derived niosomes was about 
95%.The prepared proniosomes showed marked enhancement in the dissolution of 
Celecoxib as compared to pure drug powder. The bioavailability of single dose of 
Celecoxib proniosomal formulation and a conventional marketed capsule was studied 
in human volunteers. These results show that the proniosomal formulation 
significantly improved the extend of Celecoxib absorption than the conventional 
capsule. 
3. D.Akilesh et al.
29
 developed and optimized of maltodextrin and mannitol and 
Sorbitol based proniosomes were prepared by slurry method with different surfactant 
to cholesterol ratio. All these formulations are subjected into physicochemical 
evaluations. The formulation based maltodextrin showed higher entrapment efficiency 
of 82.64 ± 1.25 and in-vitro release of of 98% at the end of 24 hr was found to be best 
among the various formulations. 
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4. Preethy Cheriyan et.al.
30
 developed maltodextrin based proniosomes of 
Cefuroxime axetil. These formulations are prepared by varying the surfactant – lipid 
loading in each formulation. All these formulations are subjected into 
physicochemical evaluations. From the results of entrapment studies, it could be 
concluded that the formulation PN4 which is having surfactant:lipid concentration as 
1:1 was the best formulation. This study suggests that the formulation can provide 
consistent and prolonged release of Cefuroxime axetil from the different niosomal 
formulations. It will lead to sustained action of the entrapped drug associated with 
frequent administration. 
5. T.Sudhamani et al.
71
 developed Ibuprofen loaded maltodextrin based proniosome 
were prepared by slurry method with different surfactant to carrier ratio. All these 
formulations are subjected into physicochemical evaluations. These results the 
formulation F4 which showed higher entrapment efficiency of 96.57 ± 1.08 % and in-
vitro cumulative drug release of 92.16% at the end of 12 hr was best formulation. 
6. Akhilesh Dubey et al.
72
 developed Lornoxicam loaded maltodextrin based 
proniosomes were prepared by slurry method with different surfactant to cholesterol 
ratio. All these formulations are subjected into physicochemical evaluations. These 
results the formulation F3 which showed higher entrapment efficiency of 72.69% and 
in-vitro release of 91.17% at the end of 24 hr,was found to be best formulation among 
the 7 formulation. Higher entrapment efficiency of the vesicles span 60 is predictable 
because of its higher alkyl chain length. The proniosomal formulations have the 
higher entrapment efficiency which might due to the high fluidity of the vesicles. 
Very low cholesterol content was found to cause low entrapment efficiency ,which 
might be because of the vesicles. 
7. Tamizharasi Sengodan et al.
33
developed Indomethacin loaded maltodexrin based 
proniosome by slurry method with different surfactant to cholesterol ratio. Preparation 
of proniosomes was optimized for highest percentage drug entrapment. All these 
formulations are subjected into physicochemical evaluations. Formulation F4 showed 
highest entrapment efficiency of 81.28 ± 4.38%w/w. The proniosomal formulations 
having low cholesterol content was found to cause low entrapment efficiency which 
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might be because of leakage of the vesicles. The higher entrapment may be explained 
by cholesterol content. These are reports that entrapment efficiency increase with 
increasing cholesterol content and by the usage of span 60 which has higher transition 
temperature. 
8. Sharda sambhakar et al .
34
 developed dry free-flowing proniosomes Cefuroxime 
axetil has been prepared with sorbitol by spray coating method. Span 40, 60 and 80 
have been used in different molar ratio with cholesterol and stearylamine. 
Proniosomes are characterized by physicochemical evaluation and ex-vivo permeation 
study. Entrapment efficiency of span 60 was found to be maximum. Both 
proniosomes and niosomes indicate the similar controlled release profile. 
9. Meenakshi K. Chauhan et al.
35
 developed maltodextrin based proniosomes to  
improve the oral delivery of Ramipril by using slurry method. All these formulations 
are subjected into physicochemical evaluations. The release rate of formulation 
compared to marketed formulation that the formulation had high encapsulation 
efficiency and provided a sustained release over 24 hr. 
10. Prakash S Goundanavar et al.
36
 developed proniosomes of Irinotecan 
hydrochloride trihydrate were prepared by slurry method using different surfactants, 
cholesterol and dicetyl phosphate. All these formulations are subjected into 
physicochemical evaluations in-vivo targeting. These results proniosomes offer a 
suitable alternative colloidal carrier approach to achieving drug targeting. 
Proniosomes containing Irinotecan are retained at targeted sites and are capable of 
releasing drug for an extended period of time. 
11. R.Parthibarajan et al.
77
 developed methotrexane entraped Proniosomes were 
prepared by slurry method using cholesterol, surfactant(span80), maltodextrin. 
Preparation of proniosomes was optimized for highest percentage drug entrapment. 
Increasing the span 80 concentration might increase the drug entrapment efficiency. 
Proniosomes could be used as a drug carrier for producing prolonged activity. 
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12.D.Akhilesh et al.
78
 developed Gliclazide loaded maltodextrin based proniosomes. 
The results reported here indicate that proniosomes are very promising as drug 
carriers. The present formulation study on Gliclazide is an attempt to prepare 
proniosome based niosomal drug delivery system using maltodextrin as carrier and to 
evaluate its performance. The proniosomes with various types and contents of 
nonionic surfactant and cholesterol is evaluated in this study. An ideal or best 
formulation of proniosomes based niosome is said to be one which gives high 
entrapment efficiency with desirable sustained release. In this study entrapment 
efficiency is found to be cholesterol:surfactant ratio dependent. The release rate also 
found to be dependent of cholesterol: surfactant ratio  for effective proniosomes. 
 
13. Ajay solanki et al.
39
 prepared, characteraized, optimization and carried out 
stability studies of Aceclofenac proniosomes. This investigation was to prepare, 
characterize and optimize the Aceclofenac proniosomes using central composite 
design and carry out stability studies. Three independent variables selected were 
molar ratio of drug to lipid (X1), surfactant loading (X2) and volume of hydration 
(X3). Based on central composite design, 16 batches of proniosomes were prepared 
by slurry method and evaluated for the percentage drug entrapment (PDE) and mean 
volume diameter (MVD). The PDE and MVD (dependent variables) and the 
transformed values of independent variables were subjected to multiple regressions to 
establish a second order polynomial equation. Contour plots were constructed to 
further elucidate the relationship between the independent and dependent variables. 
 
14. Lakshmi G. et al 40.  designed and characterized of Vinblastine sulphate loaded 
proniosome for cancer therapy . This investigation was to prepare, characterize and 
optimize the Vinblastine sulphate loaded proniosomes for overall improvement in the 
physical stability and to prolong the release time in a controlled manner there by 
increasing its efficacy and to reduce its toxicity and to study the suitability of 
proniosomes as the carrier of drug. Proniosomes of Vinblastine sulphate were 
prepared by slurry method. The results obtained for the present study clearly revealed 
that proniosomes containing Vinblastine sulphate are capable of releasing their drug 
for the extended period of time there by increasing the efficacy of drug. 
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15.B.Agaiah Goud et al.
41
 formulated and evaluated of Megesterol proniosomal 
systems. The various proniosomal systems developed were span 20:megesterol 
(50:50%), Span20:Megesterol(70:30%), Span20 50% and 50% 
Megesterol+cholesterol (50:50), and Span 20, 70% and 30% Megesterol+cholesterol 
(50:50). Out of all the compositions the one with 70% span 20 and 30% 
Megesterol:cholesterol (50:50) exhibited slower release. 
 
16. Rishu Kakkar et al.
42
 developed non-ionic surfactant vesicles of Valsartan, an 
angiotensin II inhibitor, were prepared by coacervation phase separation method. The 
prepared systems were characterised for encapsulation efficiency, shape, size and in-
vitro drug release. The encapsulation efficiency of proniosomes prepared withSpan60 
was superior to that prepared with Span 40. A preparation with 9:2:9 ratio of Span 
60,cholesterol and lecithin gave maximum encapsulation efficiency (71.50%) and 
release results (Q24h=75%) as compared to other compositions. 
 
17. Hemant N.Patil et al.44 carried out formulation development and evaluation of 
proniosomal gel of Carvedilol .To optimize the formulation, various proniosome gels 
composed of various ratios of sorbitan fatty acid esters, polysorbates, cholesterol, 
lecithin were prepared by coacervation-phase separation method. Proniosomal gel 
(PNG) formulations of Carvedilol were characterized for vesicular shape & size, 
entrapment efficiency, permeation study, stability study, pH and viscosity of gel. The 
effects of cholesterol, lecithin and different non-ionic surfactants on transdermal 
permeability profile of Carvedilol were also assessed. The percent encapsulation of 
Carvedilol in proniosome with Tween surfactants revealed a very high entrapment 
efficiency than the span surfactants. 
 
18. Madhu B.K etal.
45
 developed proniosomal formulation of Diclofenac Sodium by 
slurry method based on non-ionic surfactants (Tween 60), cholesterol and 
maltodextrin as a carrier. Four formulations were prepared using maltodextrin as a 
carrier, cholesterol, Tween 60, carbopol 934P as polymers. Proniosomal formulations 
were prepared using slurry method. The proniosomal formulation was evaluated for 
FT-IR study, scanning electronmicroscopy, stability study, In-vitro release study 
respectively. The formulation F4 which showed higher entrapment efficiency of 
77.23% with Tween 60respectively and in-vitro releases of 77.01% at the end of 24 
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hrs was found to be best among the all 4 formulations. From these results proniosomal 
formulation could be a promising deliverysystem for Diclofenac Sodium with 
improved bioavailability and better controlled drug release. 
 
19. Sandeep loona et al.
46
 developed proniosomal carrier system of Metformin 
hydrochloride for the treatment of type – 2diabetes mellitus that is capable of 
delivering entrapped drug over an extended period of time. Proniosomes of metformin 
hydrochloride were prepared by coacervation phase separation method. The potential 
of proniosomes as a transdermal drug delivery system was estimated by encapsulating 
the drug in various formulations of proniosomal gel composed of different ratios of 
Span 60/Span 40, cholesterol and lecithin. The prepared systems were characterized 
for encapsulation efficiency, size, zeta potential analysis, in-vitro drug release and 
vesicular stability at different storage conditions. The results showed that the 
encapsulation efficiency of proniosomes prepared with Span 60 was superior to that 
prepared with Span 40. A formulation (i.e. PNG2) with 9:2:9 ratio of span 60, 
cholesterol andlecithin gave maximum encapsulation efficiency (76.8 %), good zeta 
potential (-51.9) and lowest drug release percent after 24 hrs(75.9%). It is evident 
from the study that the Metformin proniosomal gel is promising prolonged drug 
delivery system and has reasonably good stability characteristics. 
 
20. Hayder K. Abbas et al.
47
 prepared  Metoprolol tartrate niosomal gel as 
transdermal drug delivery system and also to evaluate procedure related variables like 
type of surfactant and release of drug from niosomes. Metoprolol tartrate niosomes 
are formulated by coacervation-phase separation method using different types of non-
ionic surfactant, lecithin and cholesterol. The prepared formulations are estimated for 
its entrapment efficiency, vesicle size, the compatibility of the drug and additives used 
and morphological characters .Higher entrapment efficiencies are obtained with Span 
40 and span 60 (86.6%±8.07 and 78.09±15.44 respectively) and the release rate at 11 
hr from span 40 niosomes is found to be 31.18%. In conclusion, the niosomal gel 
formulation could be a promising transdermal delivery system for Metoprolol tartarate 
with prolonged drug release profiles. 
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21. Anindita D et al.
48
formulated and evaluated Tretinoin proniosomal gel and to 
carry out comparative skin irritation study with conventional Tretinoin solution and 
Tretinoin conventional gel. The proniosomal dispersion was prepared using different 
grades of non-ionic surfactants and cholesterol in different ratios along with Tretinoin. 
The proniosome vesicles prepared with Span 60, 40 and cholesterol in formulation 
PN9 showed maximum entrapment efficiency(76.77±1.54) .The prepared proniosome 
vesicles were incorporated into Carbopol gel (1%) base to prepare Tretinoin 
proniosomal gel. The In-vitro diffusion study carried out using sigma dialysis 
membrane showed sustained release pattern of Tretinoin from proniosomal gel 
formulation. 
 
22.  Peeyush Vasista et al.
49
 developed a proniosomal carrier system for Lisinopril 
and Hydrochlorothiazide (HCTZ) drug combination for prophylaxis and treatment of 
hypertension that is capable of efficiently delivering entrapped drug over an extended 
period of time. The potential of proniosomes as a transdermal drug delivery system 
for Lisinopril and hydrochlorothiazide was investigated by encapsulating the drug in 
various formulations of proniosomal gel composed of various ratios of sorbitan fatty 
acid esters, cholesterol, drug determined by factorial design and prepared by 
coacervation-phase separation method. The formulated systems were characterized  
in-vitro for size, drug entrapment, drug release profiles and vesicular stability at 
different storage conditions. The optimized formulations of HCTZ and Lisinopril 
were obtained by employing factorial design at two phases. The method of 
proniosome loading resulted in an encapsulation yield of 37.01± 1.26% and 59.94± 
1.56% for HCTZ and Lisinopril respectively. In -vitro studies of HCTZ and Lisinopril 
proniosome was carried by drug diffusion through cellophane membrane and Ex-vivo 
skin permeation studies, the percent drug released after 24 hrs was found ranging in 
79-66 % and 48-61% of total drug entrapped for Lisinopril and HCTZ respectively. 
From these  result of this study that proniosomes are a promising prolonged delivery 
system for HCTZ and Lisinopril . 
 
23.  Alpana Ram et al.
50
developed proniosomal carrier system for Hydralazine for 
prophylaxis and treatment of hypertension that is capable of efficiently delivering 
entrapped drug over an extended period of time. The potential of proniosomes as a 
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transdermal drug delivery system for Hydralazine was investigated by encapsulating 
the drug in various formulations of proniosomal gel composed of various ratios of 
sorbitan fatty acid esters, cholesterol, lecithin prepared by coacervation-phase 
separation method. The formulated systems were characterized in vitro for size, 
vesicle count, drug entrapment, drug release profiles and vesicular stability at 
different storage conditions. Vesicle size and drug permeation was greater for 
formulation containing Span 40, 60 due to its high hydrophobicity which resulted in 
smaller size of vesicle. Thus proniosomal gel will be suitable drug delivery system for 
Hydralazine HCl due to ease of preparation and incorporation of less no.of excipients. 
 
24. M.Intakhab Alam et al.
51
 worked on pharmacodynamic evaluation of 
proniosoma transdermal therapeutic gel containing Celecoxib. All the prepared 
formulations were subjected to physicochemical evaluations and anti-inflammatory 
studies. The entrapment was> 90%. The selected proniosomal gel (N1LE3)produced 
100% inhibition of paw oedema in rats up to 8 h after carrageenan injection. It 
produced 95% and 92% inhibition after 12 h and 24 h, respectively. These results 
indicate that proniosomes are a promising carrier for the transdermal delivery of 
Celecoxib. 
 
25. Thulasi Chowadry et al.
52 
studied in-vitro dynamics of ibuprofen incorporated 
proniosomal gel.  Different proniosomal gels of ibuprofen were formulated with Span 
20/Span 80 and soya lecithin using the method described in literature. In all 
formulations cholesterol concentration was kept constant.  Proniosomal gel prepared 
using Span 80 showed higher flux across the membrane due to its leaky membrane. 
The order of ibuprofen release from the proniosomal gel was 
PN2>PN4>PN1>PN3.The optimized proniosomal gel formulation PN3 containing 
Span 20 exhibited prolonged ibuprofen release profiles. Fickian diffusion mechanism 
was observed with the PN3 formulation which was due to the sustained release 
property. The results indicated that the proniosomal gel would be an effective 
transdermal delivery system for ibuprofen. 
 
26. Kapil Kumar et al.
53
developed  proniosomal carrier system of Curcumin for 
transdermal delivery. Proniosomes of Curcumin were prepared by encapsulation of 
the drug in a mixture of Span80, cholesterol and diethyl ether by ether injection 
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method, and then investigated as a transdermal drug delivery system (TDDS). The 
formulated systems were characterized for size, drug entrapment, angle of repose, 
hydration rate and vesicular stability under various storage conditions. In-vitro release 
studies were performed using albino rat skin. The method used for preparing 
proniosome resulted in an encapsulation yield of 82.3 – 86.8%.One of the 
formulations (PG1) showed prolonged in vitro drug release of 61.8% over a period of 
24 h. It is evident from this study that proniosomes are very stable and promising 
prolonged delivery system for Curcumin. 
 
27.  Dr. A.Seetha Devi et al.
54
developed  Candesartan cilexetil proniosomal gel by 
coacervation phase separation method by using different surfactants, cholesterol and 
soya lecithin in 9:1:9 and 9:2:9 ratios. The prepared proniosomal gel formulations 
were evaluated for vesicle size analysis, surface morphological studies, encapsulation 
efficiency, In-vitro drug release, ex-vivo skin permeation studies and vesicular 
stability at different storage conditions.  Encapsulation efficiency of proniosomes 
formed from Span 60, Span 40, Span20, and Span 80 was found high compared with 
proniosomes prepared from Tweens (Tween 20 and Tween 80). An optimised 
preparation with 9:2:9 ratio of Span 60, cholesterol and lecithin gave maximum 
encapsulation efficiency (92.29%) and showed drug release (95.89±0.26%) in a 
controlled manner with a flux value of 1.89 μg/cm2 /hr and permeability co efficient 
value of 0.094 cm2/hr as compared to other compositions. It is evident from this study 
that proniosomes are a promising prolonged delivery system for Candesartan cilexetil 
and have reasonably good stability characteristics. 
 
28. Sandhya P et al.
55
 developed proniosomes as a transdermal drug delivery system 
for Losartan potassium was investigated by encapsulating the drug in various 
formulations of proniosomal gel composed of various ratios of Span (sorbitan esters) 
and Tween (polyoxythylene sorbitan esters), cholesterol, lecithin prepared by 
coacervation-phase separation technique. The formulated systems were characterized 
for Vesicle physical analysis, drug entrapment, rate of spontaneity, FTIR Studies, 
in-vitro release kinetics, drug release profiles, and vesicular stability at different 
storage conditions for Losartan potassium proniosomal gel were carried out according 
to ICH Guidelines. The results showed that the type of surfactant incorporated altered 
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the entrapment efficiency of proniosomal gel and higher entrapment efficiency of 
98.24% was obtained with the proniosomal gel PNG F4. 
 
29. Varsha gadekar et al.
56
developed  non-ionic surfactant based Proniosome Gels 
of Naproxen sodium, an cox II inhibitor, were prepared by coacervation phase 
separation method. The prepared systems were characterised for encapsulation 
efficiency, shape, size and in-vitro drug release. Stability study was carried out to 
investigate the leaching of drug from the proniosomal system during storage. The 
results showed that Naproxen in all the formulations was successfully entrapped and a 
substantial change in release rate and an alteration in the encapsulation efficiency of 
Naproxen from proniosomes were observed upon varying the type of surfactant and 
cholesterol content. The encapsulation efficiency of proniosomes prepared with Span 
40:60 was superior to that prepared with all Span prepration . A preparation with Span 
40: 60, cholesterol and lecithin gave maximum encapsulation efficiency (84.61%) and 
release results (Q24h= 81%) as compared to other compositions. 
 
30. Rajesh Asija et al.
57
developed  non-ionic surfactant vesicles of Acyclovir, an 
antiviral, were prepared by coacervation phase separation method. The prepared 
systems were characterised for encapsulation efficiency, shape, size and in-vitro drug 
release scanning electron microscopy (SEM). Proniosomal prepared by using different 
polymers Span 40, Span 60, Span 20, Tween 20, Tween 80 and cholesterol and soya 
lecithin.The encapsulation efficiency of proniosomes prepared with Span 
60,cholesterol and lecithin gave maximum encapsulation efficiency (89.70%) as 
compared to other compositions.The niosomal gel formulation could be a promising 
transdermal delivery system Acyclovir with prolonged drug release profiles. 
 
31. Sundarapandian Ramkanth et al.
59
  prepared proniosome gel type transdermal 
delivery system of Atenolol was prepared by coacervation phase separation method. 
The prepared formulations were evaluated for vesicle size, entrapment efficiency, in-
vitro drug loading, and drug release studies. The release of drug had shown 
considerable improvement in controlled manner from the prepared gel formulation. It 
was observed that Span 40 & 60 (A 8) based formulations shows vesicles of minimum 
size and higher entrapment efficiency compared to the other formulations. 
Proniosomal transdermal therapeutic system (A 8) was found to be the optimized 
Review Literature 
 
MADRAS MEDICAL COLLEGE  DEPARTMENT OF PHARMACEUTICS 52 
formulation as it posses good drug release and shows permeation in a steady-state 
manner over a desired period of time. 
 
32.  Aliya Parveen etal.
60
 developed muco adhesive microspheres of Lamivudine. 
Microspheres were formulated using sodium alginate (5%) with mucoadhesive 
polymer (Chitosan 1%) and copolymer Sodium CMC HPMC, Xanthan gum (XG) in 
concentration of 1% (Chitosan1% + HPMC1%) (1%) retarding agents and 10% of 
Calcium chloride(CaCl2), Aluminum sulphate (AlSO4) as cross linking agents by 
employing Ionic Gelation Technique. Amongthe prepared microspheres (F8) 
formulation in which AlSO4 was used as cross linking agent, portray better sustained 
release for more than 12hrs. 
 
33. K.Prakash etal.
61
 developed microcapsules for the controlled release of 
Lamivudine using various cellulose polymers by the solvent evaporation method. The 
prepared microcapsules were characterized for the percent drug content, entrapment 
efficiency, FTIR, DSC, scanning electron microscopy (SEM) and in-vitro dissolution 
studies. Microcapsules were spherical and free flowing. The entrapment efficiency 
was 76-86%.The release of drug from the microcapsules extended up to 8 to 12 hours. 
FTIR and DSC thermograms showed the stable character of Lamivudine in the 
microcapsules. 
 
34. R.Ruben Singh
62
 .developed oral sustained release tablets of Lamivudine 
Hydrochloride using different natural polymers such as Chitosan, Guar gum and 
Xanthan gum. The Lamivudine Hydrochloride oral sustained release tablets were 
prepared by using wet granulation method. The formulated different ratio of oral 
sustained release tablets of Lamivudine were evaluated by different parameters. The 
prepared granules were evaluated for angle of repose, bulk density, tapped density, 
compressibility index and hausner’s ratio. The tablets were evaluated to thickness, 
weight variation test, hardness, friability, drug content, in-vitro release and kinetic 
release studies. The results conclude that FL-7 can be considered as a optimized 
formula for sustained release of drug for 24 hours. 
 
35.Varun Dasari et al.
63 
formulated and carried out in-vitro evaluation of 
Lamivudine multiunit floating dosage forms using novel lipoidal polymers. In the 
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present study, Lamivudine was selected as model drug in the design as GFDDS using 
various lipoidal/ fatty polymers. Lamivudine complies with all the requirements that 
are suitable for a drug candidate to be formulated as GFDDS, as it has specific site of 
absorption in upper part of GIT. Since the halflife of Lamivudine is around 4Hours, 
multiple doses are needed to maintain plasma concentration for a good therapeutic 
response and improved patient compliance. Prescriptional 100 mg dose of 
Lamivudine wass elected to sustain the release in order to maintain its effective 
plasma drug concentrations for 12 hours. 
 
36. Harekrishna Roy et al.
64
 developed  sustained release dosage form using various 
grades of hydrophilic polymers, Hypromellose (hydroxyl-propyl methylcellulose 
HPMC K4M, HPMC K15M and HPMC K100M) and Povidone K30 as binder 
solution in a matrix-controlled drug delivery system of Lamivudine. Six tablet 
formulations were prepared by wet granulation technique. The results obtained 
revealed that HPMC K4M at a concentration of 25% in formulation (F2) was able to 
sustain the drug release for 24 h and followed the Higuchi pattern. 
 
37. Parvin Patil et al.
65
 developed solid lipid nanoparticles of Lamivudine for brain 
targeting .Solid lipid nanoparticles prepared by using emulsion solvent diffusion 
technique. The formulation were characterized for surface morphology, size, 
percentage drug entrapment and drug release. The optimum rotation speed, resulting 
into better drug entrapment and percentage yield, was in the range of 1000-1250 
r/min. The in-vitro cumulative % release from optimized formulation was found to 
40-50% in PBS and SGF for 10 hour. 
 
38. A.Abdhul Hasan Sathali et al.
66
formulated and evaluated fast dissolving tablets 
of Lamivudine to prevent mother to child transmission (MTCT) of HIV virus in 
perinatal infants. The tablets were prepared by direct compression method, using 
various superdisintegrants like sodium starch glycolate, croscarmallose sodium, and 
crospovidone at various concentrations(2%-10%). The results of precompression 
studies reveals that the powder blends of all formulations acquire good flow 
properties. From the results of post compression studies for tablets of all formulations, 
it was concluded that the formulation containing 10% crospovidone as 
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superdisintegrants emerged as overall best formulation with lowest disintegration time 
and highest drug release rate. 
 
39. Ashish Dev et al.
67
 prepared of poly(lactic acid)/chitosan nanoparticles for anti-
HIV drug delivery Poly(lactic acid) (PLA)/chitosan (CS) nanoparticles were prepared 
by emulsion method for anti-HIV drug delivery applications. The hydrophilic 
antiretroviral drug Lamivudine was loaded into PLA/CS nanoparticles. The in-vitro 
drug release studies showed that drug release rate was lower in the acidic pH when 
compared to alkaline pH. Drug release rate was found to be higher in the 6% drug 
loaded formulation when compared to 3% drug loaded formulation. These results 
indicated that the PLA/CS nanoparticles are a promising carrier system for controlled 
delivery of anti-HIV drugs. 
 
40. Subheet Jain et al.
68
 developed ethosomes for transdermal delivery of 
Lamivudine. The optimized ethosomal formulation showed 25 times higher 
transdermalflux (68.4 ± 3.5 μg/cm2/h) across the rat skin as compared with that of 
Lamivudine solution (2.8 ± 0.2 μg/cm2/h). Results of cellular uptake study showed 
significantly higher intracellular uptake of ethosomes (85.7% ± 4.5%) as compared 
with drug solution (24.9% ± 1.9%). The results of the characterization studies indicate 
that lipid perturbation along with elasticity of ethosomes vesicles seems to be the 
main contributor for improved skin permeation. 
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3. AIM AND PLAN OF WORK 
AIM OF WORK 
      The aim of the present study is 
 To formulate Lamivudine Proniosomal drug delivery system by  two 
different methods using different non-ionic surfactants, cholesterol, 
maltodextrin and lecithin. 
 To study the effect of varying surfactant concentration on entrapment 
efficiency, drug release, and mean vesicle size. 
 To sustain the drug release of Lamivudine proniosomes. 
 To provide a safe dosage form with lesser side effects. 
 To reduce the frequency of administration thereby improving the 
patience complaince. 
PLAN OF WORK 
The present work is carried out to design and evaluate Lamivudine 
proniosomes. Conventional oral formulations of Lamivudine are administered 
multiple times a day because of its half – life (5-7 hrs). Treatment of AIDS 
using conventional formulations of  Lamivudine are found to have a many 
drawbacks, such as accumulation of drug in multidose therapy and poor 
patient complaince. So the study is carried  to overcome some of these 
problems by prolonging  the rate of drug release. 
PART-I 
 Drug excipients compatibility studies – FTIR study. 
PART-II 
 Preparation of standard curve of Lamivudine . 
PART-III 
 Preparation of Lamivudine proniosomes by slurry method using 
different non-ionic surfactants (Span 40, Span 60, Tween 60) in 
different ratio.  Concentration of Cholesterol , Maltodextrin were kept 
constant. 
 
Aim and Plan of Work 
 
MADRAS MEDICAL COLLEGE  DEPARTMENT OF PHARMACEUTICS 56 
 Preparation of Lamivudine proniosomes by coacervation phase 
separation method using different non-ionic surfactants(Span 40, Span 
60, Tween 60) in different ratio. Concentration of Cholesterol, Lecithin  
were kept constant. 
PART – IV 
 Evaluation of Lamivudine proniosomes 
 Mean Vesicle Diameter (MVD) by Binocular Microscopy. 
 Drug content 
 Entrapment efficiency by centrifugation method. 
 In-vitro release study of Proniosomal formulations and 
Lamivudine control in distilled water using dialysis 
membrane. 
PART-V 
 Comparison of Lamivudine proniosomes prepared  by slurry 
method and coacervation phase separation method using 
entrapment efficiency and in-vitro drug release. 
 To study the effect of surfactant concentration on entrapment 
efficiency, drug release, mean vesicle size. 
 Optimization of best method from the methods (slurry method/ 
coacervation phase separation method). 
 Optimization of best surfactant from slurry method using 
entrapment efficiency and in-vitro drug release. 
PART – VI 
 In-vitro release study and release kinetics of optimized 
formulation. 
PART – VII 
 Morphological studies of optimized formulation using Scanning 
Electron Microscopy. 
PART – VII 
 Stability studies of optimized formulation. 
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4. RATIONALE OF THE STUDY 
RATIONALE OF THE WORK
32 
Although considerable progress has occurred in the development of the 
therapy for AIDS, the available antiretroviral drugs are not always effective, are 
frequently toxic and do not clear virus from the tissue reservoirs. The major aspect 
that makes HIV dangerous disease, is its ability to replicate itself. We could not find a 
cure so far due to the mutation process, which this virus undergoes resulting in the 
formation of several  mutant groups. There are basically two strains of HIV virus : 
HIV1 and HIV2. HIV1 accounts for 95% of all infections worldwide.HIV2 is mainly 
seen in West African countries. 
 Antiretroviral(ARV) drugs are broadly classified by the phase of the retrovirus 
life –cycle that the drug inhibits. They are 
 Nucleooside and Nucleotide reverse transcriptase inhibitors 
(NRTIs) 
 Non- Nucleotide reverse transcriptase inhibitors (NNRTIs) 
 Protease inhibitors 
 Integrase  inhibitors 
 Maturation inhibitors 
 Nucleoside  and Nucleotide reverse transcriptase inhibitors inhibit reverse 
transcription by being incorporated into the newly synthesized viral DNA strand as 
afaulty nucleotide. This causes a chemical reaction resulting in DNA chain 
termination. Non-Nucloside reverse transcriptase inhibitors inhibit reverse 
transcriptase directly by binding to the enzyme and interfering with its function. 
SELECTION OF FORMULATION
26 
Proniosomes is a surfactant coated vesicular drug delivery system. It is more 
advantageous over liposomes and niosomes because, 
 Liposomes and niosomes are dispersed aqueous system and have a problem 
ofdegradation by hydrolysis or oxidation. 
 Liposomes and niosomes require special storage and handling. 
 Sedimentation, Aggregation or fusion on storage is usually seen. 
 In liposomes, purity of natural phospholipids is also variable. 
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 Difficulty in sterilization,  transportation, distribution, storage uniformity of 
dose and scale up. 
RATIONALE FOR SELECTION OF THE DRUG 
Lamivudine is one of the dideoxycytidine analogue Nucleoside Reverse 
Transcriptase inhibitor (NRTs) is the first nucleoside analogue to treat AIDS and 
chronic HBV infection. Lamivudine can be used in both cases of HIV (type 1 and 
type 2). 
             As there is no complete cure for the HIV, the patient has to take continuous 
medication to extend the lifespan but to continuous medication to the patient there 
occurs a lot of side effects and adverse effects of the high amount of dose 
administered daily with the conventional dosage form. In order to overcome the 
problem of frequent dosing of Lamivudine, the prolonged drug delivery system of 
proniosomes containing  Lamivudine formulated. 
SELECTION OF MATERIALS 
The materials are selected in order to produce non-toxic, smaller homogenous 
discrete vesicles having high entrapment of drug. 
Surfactant 
24 
 The non-ionic surfactants (Sorbitan Monoesters) are selected for producing 
non-toxic drug delivery systems. 
 The non-ionic surfactants are having permeation enhancement property. 
 Among all the spans (Sorbitan Monoesters), the Span 60 Shows high 
entrapment ofdrug.  
Cholesterol 
24 
 Cholesterol is used as a membrane stabilizers. 
 It resembles the biological membrane. 
 Non-toxic. 
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Lecithin 
24 
 Phosphatidyl choline is used as a membrane stabilizer. 
 The egg lecithin is preferred over the soya lecithin because, the egg lecithin 
produce thesmaller vesicles. 
 
Maltodextrin
 22 
 It is a mixture of glucose, disaccharides and polysaccharides, obtained by the 
partial hydrolysis of starch.  
 Maltodextrin is a flavorless, easily digested carbohydrate made from 
cornstarch. A maltodextrin is a short chain of molecularly linked dextrose 
(glucose) molecules, and is manufactured by regulating the hydrolysis of 
starch.  
 A white or almost white, slightly hygroscopic powder or granules, freely 
soluble in water. 
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DISEASE PROFILE
7,31,32,38 
 
Figure:6 Human immuno deficiency virus 
 
 Human immunodeficiency virus (HIV) is the causative agent for AIDS. The 
most common type is known as HIV -1 and is the infectious agent that has led to the 
worldwide AIDS epidemic. These is also an HIV -2 that is much less common and 
less virulent, but eventually produces clinical findings similar to HIV-1. The HIV-1 
type itself has a number of subtypes (A through H and O) which have differing 
geographic distributions but all produces AIDS similarly. HIV is a retrovirus that 
contains only RNA. 
               HIV is a sexually transmitted disease. Infection is aided by Langerhans cells 
in mucosal epithelial surfaces which can become infected. Infection is also aided by 
the presence of other sexually transmitted diseases that can produce mucosal 
ulceration and inflammation. The CD4+ T-lymphocytes have surface receptors to 
which HIV can attach to promote entry into the cell. The infection extends to 
lymphoid tissues which contain follicular dendritic cells that can become infected and 
provide a reservoir for continuing infection of  CD4+ T-lymphocytes. HIV can also 
spread via blood products, most commonly with shared contaminated needles used by 
persons engaging in intravenous drug use. Mothers who are HIV infected can pass the 
virus on to their foetuses in utero or to infants via breast milk. 
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 When HIV infects a cell,it must use its reverse transcriptase enzyme to 
transcribe  its RNA to host cell proviral  DNA. It is this proviral DNA that directs the 
cell to produce additional HIV virions which are released. When the CD4 lymphocyte 
count drops below 200/microliter, then the stage of clinical AIDS has been reached. 
             Lamivudine is an potential anti-HIV agent, used for the long term treatment 
of HIV-1 infection. It is approved by the U.S Food and Drug Administration (FDA). 
Lamivudine treatment in the present era. Dosage and duration of Lamivudine therapy 
should be individualized according to requirement and response of the patient. 
 
 
Figure:7 HIV Structure 
HIV consists of a cylindrical center surrounded by a sphere-shaped lipid 
bilayer envelope. There are two major viral glycoproteins in this lipid bilayer, gp120 
and gp41. The major function of these proteins is to mediate recognition of CD4+ 
cells and chemokine receptors, thereby enabling the virus to attach to and invade 
CD4+ cells. The inner sphere contains two single-strandedcopies of the genomic 
material, RNA, as well as multiple proteins and enzymes necessary for HIV 
replication and maturation: p24, p17, reverse transcriptase, integrase, and protease . 
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LIFE CYCLE OF HIV VIRUS 
 
 
Figure:8  HIV Life cycle 
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TRANSMISSION OF HIV 
 Unprotected sexual intercourse, especially receptive anal intercourse . 
 A large number of sexual patners. 
 Prior or current sexually transmitted diseases (STDs): 
 Gonorrhea and Chlamydia infections the HIV transmission risk 3-
fold syphilis raises the transmission risk 7-fold. 
 Herpes genitalis raises the transmission risk up to 25-fold during an 
outbreak. 
 Mucosal contact with infected blood or needle-stick injuries. 
 Maternal HIV infection ( for newborns, infants and children): 
              Steps taken to reduce the risk of transmission at birth include 
cesarean delivery and prenatal antiretroviral therapy in the mother and 
antiretroviral therapy in the newborn immediately after birth. 
HIV is not transmitted by 
 Coughing, sneezing. 
 Insect bites. 
 Touching. 
 Water and food. 
 Hand shaking. 
 Using telephones. 
 Sharing cups, glasses, plates or other utensils. 
Methods to reduce rates of HIV Transmission 
 Treat HIV infection as an illness, not as a social stigma. 
 Provide HIV testing and counseling to identify infected persons who can 
reduce their risk to others. 
 Provide educational programs for children and adults which describe how to 
avoid. 
 Immediate treatment of sexually transmitted diseases. 
 Provide clean sterile needles for injection drug. 
 Create HIV-infected pregnent women antiretroviral therapy to reduce 
perinatal HIV transmission. 
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 Consider pre-exposure Prophylaxis with antiretroviral drugs. 
STAGES OF HIV INFECTION
38 
HIV infects cells in the immune system and the central nervous system. One 
of the main type of cells that HIV infects is the T helper lymphocyte. These cells play 
a crucial role in the immune system. A large reduction in the number of T helper cells 
seriously weakens the immune system. 
             HIV infects the T helper cell because it has the protein CD4 on its surface, 
which HIV uses to attach itself to the cell before gaining entry. This is the reason T 
helper cell is sometimes referred to as a CD4+ lymphocyte. Once it has found its way 
into a cell,HIV produces new copies of itself, which can then go on infect other cells. 
            HIV infection leads to a severe reduction in the number of T helper cells 
available to help fight disease. The number of T helper cells is measured by having a 
CD4 test and is referred to as the CD4 count. It can take several years before the CD4 
count declines to the point that an individual needs to begin antiretroviral treatment. 
Without treatment, the CD4 count continues to decline to very low levels, at which 
point the individual is said to have progressed to AIDS.  
HIV infection can generally be broken down into four distinct stages: 
 Primary infection 
 Clinically asymptomatic stage 
 Symptomatic HIV infection 
 Progression from HIV to AIDS 
STAGE 1: Primary Infection 
This stage of infection lasts for a few weeks and is often accompanied by a 
short flu-like illness. About 20% of the people the HIV symptoms are serious enough 
to consult a doctor, but the diagnosis of HIV infection is frequently missed. During 
this stage there is a large amount of HIV in the peripheral blood and the immune 
system begins to respond to the virus by producing HIV antibodies and cytotoxic 
lymphocytes. This process is known as seroconversion. If an HIV antibody test is 
done before seroconversionis complete then it may not be positive.  
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STAGE 2: Clinically asymptomatic stage 
 This stages lasts for an average of ten years and as its name suggests, is free 
from major symptoms, although there may be swollen glands. The level of HIV in the 
peripheral blood drops to very low levels is but people remain infectious and HIV 
antibodies are detectable in the blood, so antibody test will show a positive result. 
STAGE3 : Symptomatic HIV infection 
Over time immune system becomes severely damaged by HIV. This is thought to 
happen for three main reasons: 
 The lymph nodes and tissues become damaged or ‘burnt out’ because of 
the years of activity. 
 HIV mutates and become more pathogenic , in other words stronger and 
more varied, leading to more T helper cell destruction. 
 The body fails to keep up with replacing the T helper cells that are lost. 
 
Antiretroviral treatment is usually started once an individual CD4 count 
i.e the number of T helper cells drops to a low level, an indication that the 
immune system is deteriorating. Treatment can stop HIV from damaging the 
immune system, therefore, HIV –infected individuals on treatment usually 
remain clinically asymptomatic. However ,in HIV-infected individuals not 
receiving treatment or on treatment that is not working, the immune system 
fails and symptoms develop. Initially many of the symptoms are mild , but as 
the immune system deteriorates the  symptoms worsen. 
 Symptomatic HIV infection is mainly caused by the emergence of 
certain infections that the immune system would normally prevent. This stage 
of HIV infection is often charecterised by multi-system disease and infections 
can occur in almost all body systems. 
 Treatment for the specific infection is often carried out, but the 
underlying cause is the action of HIV as it erodes the immune system. Unless 
HIV itself can be slowed down the symptoms of immune suppression will 
continue to worsen. 
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STAGE 4: Progression from HIV to AIDS 
 As the immune system becomes more and more damaged the 
individual may develop increasingly severe infections and cancers, leading 
eventually  an AIDS diagnosis. 
 A clinical criteria is used by WHO diagnose the progression to AIDS, 
this differs slightly between adults and children under five. In adults and 
children (aged 5 or over) the progession to AIDS is diagnosed when any 
condition listen in clinical listed in clinical stage 4 is diagnosed or the CD4 
count is less than 200 cells/mm or a CD4 percentage less than 15. In children 
younger than five, an AIDS diagnosis is based on having any stage 4 
condition and/or a CD4 percentage less than 20 (children aged 12 – 35 
months) and a CD4 percentage less than 25 (children less than 12 months). 
SIGNS AND SYMPTOMS
31 
The patient with HIV may present with signs and symptoms of any of the stages 
of HIV infection. No physical findings are specific to HIV infection. Manifestations 
include the following: 
 Acute seroconversion manifests as a flu like illness, consisting of fever, 
malaise and a generalized rash. 
 The asymptomatic phase is generally benign. 
 Lymphadenopathy is common. 
 AIDS manifests as recurrent, severe and occationally life-threatening 
infections or malignancies. 
 AIDS associated dementia/encephalopathy and HIV wasting syndrome 
(chronic diarrhea and weight loss with no indentifiable causes). 
 Highly active antireteroviral therapy (HAART) is the principle method  for 
preventing immune deterioration. Classes of antireteroviral agents include the 
following: 
 Nucleooside and Nucleotide reverse transcriptase inhibitors 
(NRTIs) 
 Non- Nucleotide reverse transcriptase inhibitors (NNRTIs) 
 Protease inhibitors (PIs) 
 Fusion inhibitors 
 HIV integrase strand transfer inhibitors 
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 There has been improvement over time . Between 1996 and 2010 the rate of 
new HIV infections fell by 56 %. This trend is mainly due to a drop in infections in 
southern states; in other areas there has been no significant decline. 
 
 
 
TREATMENT
6
 
HIV is treated using a combination medicines to fight HIV infection . This is 
called antireteroviral therapy (ART). ART it is not cure , but it can control the virus so 
that you can live longer, healthier life and reduce the risk of transmitting HIV to 
others. 
         These HIV medicines prevent HIV from multiplying , which reduces the amount 
of HIV in our body gives immune system a chance to recover and fight off infections. 
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Table :5 Preferred and alternative anti-HIV regimens 
 
 
                                     Preferred regimens 
2 NRTI + NNRTI (PI sparing) 
1. Zidovudine + lamivudine + efavirenz 
2 NRTI + PI 
1. Zidovudine + lamivudine + lopinavir 
                                       Alternative regimens 
2 NRTI + NNRTI (PI sparing) 
1. Zidovudine + lamivudine + nevirapine 
2. Lamivudine + stavudine + efavirenz 
3. Lamivudine + stavudine + nevirapine 
4. Lamivudine + abacavir + efavirenz 
5. Lamivudine + abacavir + nevirapine 
2 NRTI + PI 
1. Lamivudine + zidovudine + indinavir 
2. Lamivudine + stavudine + ritonavir 
3. Lamivudine + abacavir + lopinavir/r 
4. Lamivudine + abacavir + nelfinavir 
3 NRTI* 
1. Zidovudine + lamivudine + abacavir 
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BLOOD DETECTION TEST : 
 
 Enzyme- Linked Immunosorbent Assay/Enzyme Immunoassay (ELISA/EIA). 
 Radio Immuno Precipitation Assay/Indirect Fluorescent Antibody Assay 
(RIP/IFA). 
 Polymerase chain Reaction (PCR). 
 Western blot Confirmatory test. 
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6. DRUG PROFILE
6,8,37,38 
Lamivudine is an antiviral drug. It is a novel cystosine  nucleoside analog, 
reverse transcriptase inhibitor that has shown activity against Human 
Immunodeficiency Virus (HIV) types1 and 2 and hepatitis B virus. 
 
Physicochemical profile 
      Official status           :    I.P, USP 
Structure                   
 
 
  
Drug name : Lamivudine    
Molecular formula  :  C8H11 N3O3S 
Molecular weight       : 229.26 g/mol 
Melting point          : 186
    –      C 
Chemical name           : 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-
oxathiolan- Yl]-1,2-dihydropyrimidin-2-one. 
CAS number : 134678-17-4 
Category : Anti-HIV Agents Nucleoside Reverse Transcriptase 
Inhibitors 
Description                : A white or almost white powder 
Solubility           : Soluble in water , sparingly soluble in methanol, 
practically insoluble in acetone.  
Bioavailability    : 86 % 
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Protien binding         : < 36 % 
Half life (t1/2)             : 5 – 7 Hours 
Cmax   : About 1.5 hours 
 
Pharmacology 
Lamivudine is an analogue of  2’3’-dideoxynucleoside 3’-thia cytidine. It can  
inhibit both types ( 1 and 2) of HIV reverse transcriptase and also the reverse 
transcriptase of hepatitis B. Lamivudine   undergoes intracellular phosphorylation by 
kinases to form the pharmacologically active moiety 3TCTP that compete for 
incorporation into viral DNA . They inhibit the HIV reverse transcriptase enzyme 
competitively and act as a chain  terminator of DNA synthesis. The lack of a 3’-OH 
group in the incorporated nucleoside analogue prevents the formation of the 5’ to 
3’phosphodiester linkage essential for DNA chain elongation , and therefore, the viral 
DNA growth is terminated. 
  
 Pharmacodynamics 
   Lamivudine tri phosphate competes with deoxycytidine triphosphate for 
binding to reverse transcriptase and the incorporation of 3TC-triphosphate agent 
form in viral DNA results in chain termination. 
Mechanism 
During infection with HIV, the HIV virus multiplies within the body’s cells. 
The viruses then are released from the cells and spread throught out the body where 
they infect other cells. In this manner, HIV infection spreads to new , uninfected 
cells that the body is continually producing and HIV infection perpetuated. When 
producing new viruses, the HIV virus must manufacture new DNA for each virus. 
Reverse transcriptase is the virus enzyme that forms this new DNA. Lamivudine is 
converted within the body to its active form, lamivudine triphospate. This active 
form is similar to a chemical, deoxycytidine triphosphate, that is used by reverse 
transcriptase to make new DNA. The reverse transcriptase uses lamivudine 
triphosphate instead of deoxycytidine triphosphate , and the lamivudine  
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triphosphate interfers with the reverse transcriptase. Lamivudine does not kill 
existing HIV virus and it is not a cure for HIV. 
 
Pharmacokinetics 
 Absorption 
Lamivudine was rapidly adsorbed after oral administration in HIV- 
infected patients. Following an oral dose, reaching maximal serum 
concentrations between 1 and 1.5 h, has good ( > 80 %) absolute 
bioavailability. The influence of food on lamivudine absorption is not 
considered. Hence lamivudine can be given with or without food. 
 Distribution 
86 % of lamivudine distributes into extravascular spaces. Volume of 
distribution was independent of dose and did not correlate with body weight. 
In pregnant women, lamivudine concentrations in maternal serum, amniotic 
fluid , umbilical cord and neonatal serum are comparable, indicating that the 
drug diffuses freely across the placenta. In postpartum women lamivudine is 
secreted into breast milk. 
 Metabolism 
           The only detected metabolite of lamivudine is trans-sulfoxide. 
Intracellularly it is metabolized to its active triphospate form by multiple 
kinase. 
 Elimination 
           Renal clearance is the major route of lamivudine elimination. 
Following oral administration 70 % dose is excreted unchanged in the urine 
and only 5- 10 % undergoes hepatic metabolism to form a trans-sulfoxide 
which is then also renally eliminated. Lamivudine is excreted in human 
breast milk. 
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Dosage 
Lamivudine  
Tablets               :   100,150 and 300 mg 
 Oral solution     :    5,10 mg/ml  
 Oral solution 
Neonates ( < 1 month)                  -    2 mg/kg twice daily. 
Infants and children (< 16 years)  -    4mg/kg twice daily. 
 
 Tablets  
   Adults ( > 16 years )   : 150 mg every 12 hours 
 
 Combination  
o 150 mg Lamivudine and 300mg Zidovudine 
o 300mg Abacavir and 150mg  Lamivudine and 300 mg   Zidovudine 
 
ADVERSE EFFECTS 
 Head ache 
 Dizziness  
 Nausea  
 Vomiting  
 Chills 
 Cough  
 Loss of appetite 
 Fatigue  
 Abdominal pain 
 Anorexia  
 Weight loss  
 Diarrheoa 
 Lactic acidosis 
 Changes in body fat. 
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Precautions 
         Precautions has to be taken in people having kidney or liver disease or history 
of pancreatitis, diabetes, pregnancy and nursing mothers. 
Contraindications 
         Drug resistance to Anti-reteroviral therapy, severe liver disease , acute and 
chronic inflammation of the pancreas, kidney disease , Nursing mothers , increased 
blood Acidity due to high  levels of Lactic Acid, Overweight. 
Drug interactions 
        Tobramycin          - Increased risk of nephrotoxicity 
         Valganiciclovir     - risk of hematologic toxicity 
         Zalcitabine            - reduce the  efficacy of lamivudine 
        Trimethoprim         - Increases concentration of Lamivudinein blood 
         Ribavir                   - Increases the risk of lamivudine side effects. 
 
Uses 
        To prevent HIV infections 
        At low doses used to treat chronic Hepatitis B. 
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SORBITAN MONOPALMITATE
8
 
SYNONYMS 
Arbunol S-40; Alracel 40; Crill 2; Liposorb P; Montane 40; Sorbitanpalmitate; 
Span 40. 
CHEMICAL NAME 
Sorbitan Mono Hexadecanoate 
EMPIRICAL FORMULA 
 C22H42O6 
MOLECULAR WEIGHT 
 403 
STRUCTURE 
 
DESCRIPTION 
 Creamy solid 
PROPERTIES 
 Acid value   - 3- 7 
 Hydroxyl value  - 270- 303 
 Saponification value - 142- 152 
 Melting point  - 43- 48°C 
 Density (g/cm3)  - 1.0 g/cm3 
 HLB value  - 6.7 
 
FUNCTIONAL CATEGORY 
 Emulsifying agent 
 Non- ionic surfactant 
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 Solubiizing agent 
 Wetting agent 
 Dispersing/ Suspending agent 
STABILITY 
 Gradual soap formation occurs with strong acids or bases 
 Stable in weak acids or bases. 
STORAGE 
 It should be stored in a well- closed container in a cool, dry place. 
SAFETY 
 Daily intake according to the WHO limit is about 25 mg/ kg body weight. 
HANDLING PRECAUTIONS 
 Eye protection and Gloves are recommended. 
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SORBITAN MONOSTEARATE
8 
SYNONYM 
Arbunol S- 60; Alracel 60; Crill 3; Liposorb S-K; Montane 60; Sorbitan 
stearate; Span 60; Tego SMS. 
CHEMICAL NAME 
 Sorbitan Mono- Octadecanoate 
EMPIRICAL FORMULA 
 C24H46O6 
MOLECULAR WEIGHT 
 431 
STRUCTURE 
 
DESCRIPTION 
 Cream solid 
PROPERTIES 
 Acid value   - 5- 10 
 Hydroxyl value  - 235- 260 
 Saponification value - 147- 157 
 Melting point  - 53- 57°C 
 HLB value  - 4.7 
FUNCTIONAL CATEGORY 
 Emulsifying agent 
 Non- ionic surfactant 
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 Solubilizing agent 
 Wetting agent 
 Dispersing/ Suspending agent 
STABILITY 
 Gradual soap formation occurs with strong acids or bases 
 Stable in weak acids or bases. 
STORAGE 
 It should be stored in a well- closed container in a cool, dry place. 
SAFETY 
 Daily intake according to the WHO limit is about 25 mg/ kg body weight. 
HANDLING PRECAUTIONS 
 Eye protection and Gloves are recommended. 
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POLYSORBATE 60
8 
SYNONYM 
Atlas 70K; Crillet 3; Glycosporse S- 20; Liposorb S- 20; Polyoxyethylene 
20 stearate; Sorbitanmonooctadecanoate; Tween 60; Tween 60 K; Tween 60 VS. 
CHEMICAL NAME 
 Polyoxyethylene 20 SorbitanMonostearate 
EMPIRICAL FORMULA 
 C64H126O26 
MOLECULAR WEIGHT 
 1312 
STRUCTURE             
DESCRIPTION 
 Yellow oily liquid 
PROPERTIES 
 Acid value   - 2.0 
 Hydroxyl value  - 81- 96 
 Saponification value - 45- 55 
 Melting point  - 53- 57°C 
 HLB value  - 14.9 
 Solubility   -soluble in ethanol and water. 
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FUNCTIONAL CATEGORY 
 Emulsifying agent 
 Non- ionic surfactant 
 Solubilizing agent 
 Wetting agent 
STABILITY 
 Stable to electrolytes and weak acids and bases 
 Gradual saponification occurs with strong acids and bases 
 It is hygroscopic and should be examined for water content prior to use 
and dried if necessary 
 Also, in common with other polyoxyethylene surfactants, prolonged 
storage can lead to the formation of peroxides. 
STORAGE 
 It should be stored in a well- closed container protected from light, in a cool, 
dry place. 
SAFETY 
Daily intake according to the WHO limit is about 25 mg/ kg body weight and 
moderately toxic by i.v. route 
HANDLING PRECAUTIONS 
Eye protection and Gloves are recommended. 
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CHOLESTEROL
8 
SYNONYM 
 Cholesterolum; Cholesterin 
CHEMICAL NAME 
 Cholest- 5-en-3β- ol 
EMPIRICAL FORMULA 
 C27H46O 
MOLECULAR WEIGHT 
 386.67 
STRUCTURE 
 
FUNCTIONAL CATEGORY 
 Emulsifying agent 
 Emollient 
DESCRIPTION 
 Cholesterol occurs as white or faintly yellow, almost odourless, pearly 
leaflets, needles, powder or granules. 
 On prolonged exposure to light and air, it acquires a yellow to tan colour. 
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PROPERTIES 
 Boiling point - 360°C 
 Density  - 1.052 g/ cm3 for anhydrous form 
 Melting point - 147- 150°C 
 Solubility   - Soluble in acetone and vegetable oils 
Practically insoluble in water, Soluble in chloroform:               
methanol mixture. 
STABILITY AND STORAGE CONDITIONS 
 It is stable, and should be stored in a well- closed container and protected from 
light. 
SAFETY 
It is generally regarded as an essentially non- toxic and non- irritant material at 
the levels employed as an excipients. 
HANDLING PRECAUTIONS 
 Rubber or plastic gloves, eye protection and a respirator are recommended. 
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LECITHIN
8 
SYNONYM 
Egg lecithin; mixed soybean phosphatides; ovolecithin; ; soybean lecithin; 
soybean phospholipids;  vegetable lecithin. 
CHEMICAL STRUCTURE: 
 
CHEMICAL NAME: 
1,2-diacyl-sn-glycero-3-phosphocholine. 
DESCRIPTION: 
Lecithins vary greatly in their physical form, from viscous semisolids to 
powders, depending upon the free fatty acid content. They may also vary in color 
from brown to lightyellow. When they are exposed to air, rapid oxidation occurs, also 
resulting in a dark yellow or brown color. Lecithins are soluble in aliphatic and 
aromatic hydrocarbons, halogenated hydrocarbons, mineral oil, and fatty acids. They 
are practically insoluble in cold vegetable and animal oils, polar solvents, and water. 
When mixed with water, however, lecithins hydrate to form emulsions. 
PROPERTIES: 
Density   : 0.5 g/cm3 for powdered lecithin. 
Iodine number   : 82–88 for powdered lecithin. 
Isoelectric point   : ≈3.5 
Saponification value   : 196. 
USES:    
 Emollient; emulsifying agent;  solubilizing agent, vesicle stabilizing agent. 
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MALTODEXTRIN
8 
Synonyms 
C*Dry MD,Malta*Gran;Rice,Tapi. 
Chemical Name 
Maltodextrin 
Empirical Formula  
          (C6H10O5)n·H2O 
Molecular Weight 
            900–9000 
Stucture 
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Functional Category 
Coating agent; tablet and capsule diluents, tablet binder; viscosity-increasing 
agent. 
Description 
Maltodextrin occurs as a non sweet, odorless, white powder or granules. The 
solubility, hygroscopicity, sweetness, and compressibility of maltodextrin increase as 
the DE increases. The USPNF 23 states that it may be physically modified to improve 
its physical and functional characteristics. 
Solubility: 
Freely soluble in water; slightly soluble in ethanol (95%). Solubility increases 
as DE increases. 
Stability and Storage Conditions 
Maltodextrin is stable for at least 1 year when stored at a cool temperature 
(<30°C) and less than 50% relative humidity. Maltodextrin solutions may require the 
addition of an antimicrobial preservative. Maltodextrin should be stored in a well-
closed container in a cool, dry place. 
Handling Precautions 
           Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection is recommended. Maltodextrin should be handled in 
a well ventilated environment and excessive dust generation should be avoided. 
Use 
Diluent in single unit dosage form, coating agents, binding agent. 
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9. RESULTS AND DISSCUSION 
DRUG EXCIPIENT COMPATIBILITY STUDIES 
The possibilities of drug- excipient (cholesterol, nonionic surfactant) 
interactions were investigated by recording the FT- IR spectrum. The FT- IR 
spectra of the drug and the formulations  are shown below. 
Figure11: FT- IR spectra of Lamivudine standard 
 
Table 11: Interpretation: 
S.No. 
WAVE 
NUMBER (cm
-1
) 
CHARACTERISTICS 
1 3327.35 -NH stretching 
2 3270.45 -O- H stretching 
3 2960.86 
Aliphatic  C-H 
stretching 
4 3076.59 Aromatic C-H streching 
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Figure12: FT- IR spectra of Lamivudine with Span 40
Table 12: Interpretation: 
S.No. 
WAVE 
NUMBER (cm
-1
) 
CHARACTERISTICS 
1 3327.35 -NH stretching 
2 3270.45 -O- H stretching 
3 2960.86 
Aliphatic  C-H 
stretching 
4 3076.59 Aromatic C-H streching 
 
      It is confirmed that there is no major shifting as well as loss of functional 
peaks between the spectra of drug and Span 40. It is concluded that there is no 
interaction between the drug and excipients i.e. the drug is compatible with Span 40
27
. 
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Figure113: FT- IR spectra of Lamivudine with Span 60
Table 13: Interpretation: 
S.No. 
WAVE 
NUMBER (cm
-1
) 
CHARACTERISTICS 
1 3327.35 -NH stretching 
2 3270.45 -O- H stretching 
3 2960.86 
Aliphatic  C-H 
stretching 
4 3076.59 Aromatic C-H streching 
 
       It is confirmed that there is no major shifting as well as loss of functional 
peaks between the spectra of drug and Span 60. It is concluded that there is no 
interaction between the drug and excipients . The drug is compatible with Span 60
27
. 
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Figure14: FT- IR spectra of Lamivudine with Tween 60
Table 14: Interpretation: 
S.No. 
WAVE 
NUMBER (cm
-1
) 
CHARACTERISTICS 
1 3327.35 -NH stretching 
2 3270.45 -O- H stretching 
3 2960.86 
Aliphatic  C-H 
stretching 
4 3076.59 Aromatic C-H streching 
 
      It is confirmed that there is no major shifting as well as loss of functional 
peaks between the spectra of drug and Tween 60. It is concluded that there is no 
interaction between the drug and excipients . The drug is compatible with Tween 60
27
. 
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Figure15: FT- IR spectra of Lamivudine with Cholesterol 
Table 15: Interpretation: 
S.No. 
WAVE 
NUMBER (cm
-1
) 
CHARACTERISTICS 
1 3327.35 -NH stretching 
2 3270.45 -O- H stretching 
3 2960.86 
Aliphatic  C-H 
stretching 
4 3076.59 Aromatic C-H streching 
 
      It is confirmed that there is no major shifting as well as loss of functional 
peaks between the spectra of drug and cholesterol.  It is concluded that there is no 
interaction between the drug and excipients . The drug is compatible with cholesterol 
27
. 
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Figure16: FT- IR spectra of Lamivudine with Maltodextrin 
Table 16: Interpretation: 
S.No. 
WAVE 
NUMBER (cm
-1
) 
CHARACTERISTICS 
1 3327.35 -NH stretching 
2 3270.45 -O- H stretching 
3 2960.86 
Aliphatic  C-H 
stretching 
4 3076.59 Aromatic C-H streching 
 It is confirmed that there is no major shifting as well as loss of functional 
peaks between the spectra of drug and maltodextrin. It is concluded that there is no 
interaction between the drug and excipients .The drug is compatible with maltodextrin 
27
. 
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Figure17: FT- IR spectra of FS3
Table 17: Interpretation: 
S.No. 
WAVE 
NUMBER (cm
-1
) 
CHARACTERISTICS 
1 3327.35 -NH stretching 
2 3270.45 -O- H stretching 
3 2960.86 
Aliphatic  C-H 
stretching 
4 3076.59 Aromatic C-H streching 
 
      It is confirmed that there is no major shifting as well as loss of functional 
peaks between the spectra of drug and proniosomal formulation. It is concluded that 
there is no interaction between the drug and excipients
27
. 
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STANDARD CURVE FOR LAMIVUDINE 
The UV Spectrophotometric method was used to analyse Lamivudine. The 
absorbance of the drug in distilled water was measured at a wavelength of 270 
nm. The results are given in Table18 and Figure 18. 
Table18: Data for Calibration Curve of Lamivudine 
S. No. Concentration (µg/ ml) Absorbance at 270 nm 
1 0 0 
2 2 0.076±0.011 
3 4 0.156±0.01 
4 6 0.249±0.0098 
5 8 0.332±0.0094 
6 10 0.428±0.019 
                                                          *Mean± SD (n=3) 
 
Figure 17: Calibration curve 
The standard curve of Lamivudine in distilled water was linear in 2 to 10 µg/ ml 
concentrations. 
 
 
 
y = 0.042x - 0.007 
R² = 0.999 
-0.1
0
0.1
0.2
0.3
0.4
0.5
0 2 4 6 8 10 12
A
b
so
rb
an
ce
 a
t 
2
7
0
 n
m
 
Concentraion (µg/ml) 
Calibration curve for Lamivudine 
Results and Discussion 
 
MADRAS MEDICAL COLLEGE  DEPARTMENT OF PHARMACEUTICS 108 
 
EVALUATION RESULTS OF LAMIVUDINE PRONIOSOMES BY 
SLURRY  METHOD 
 
 
Table 19:  Formulation table 
 
 
 
 
 
 
 
FORMULATION   
CODE 
NON – IONIC 
SURFACTANT 
DRUG 
(mg) 
MALTODEXTRIN:
SURFACTANT: 
CHOLESTEROL 
(mg) 
FS1  
 
SPAN 40 
300 100:100:100 
FS2 300 100:200:100 
FS3 300 100:300:100 
FS4  
 
SPAN 60 
300 100:100:100 
FS5 300 100:200:100 
FS6 300 100:300:100 
FS7  
 
TWEEN 60 
300 100:100:100 
FS8 300 100:200:100 
FS9 300 100:300:100 
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Table 20 :Mean vesicle size, drug content and entrapment efficiency of 
Lamivudine proniosomes by slurry method 
 
FORMULATION   
CODE 
NON – IONIC 
SURFACTANT 
MEAN 
VESICLE 
SIZE 
(µm) 
% DRUG 
CONTENT 
(% w/w) 
% 
ENTRAPMENT 
EFFICIENCY 
(% w/w) 
FS1  
 
SPAN 40 
2.94 95.92 76.24 
 
FS2 5.49 98.85 71.13 
FS3 8.04 90.67 95.02 
FS4  
 
SPAN 60 
6.69 97.67 82.05 
FS5 7.83 91.62 83.33 
FS6 9.12 84.75 85.54 
FS7  
 
TWEEN 60 
8.22 101.1 45 
FS8 11.46 74.25 55.86 
FS9 13.32 97.10 86.85 
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Figure19 : Particle size distribution of Lamivudine proniosome powder 
 
 
 
 
       Lamivudine proniosomes  prepared using Span 40,Span 60 and Tween 60 at 
various concentrations . The  particle size of the hydrated proniosomes  powder was 
measured using an binocular microscope with calibrated eyepiece micrometer. From 
every batch about 100 vesicles were measured  individually and the average diameter 
was calculated. The average vesicular size of hydrated niosomes was in the range of 
2.94 to 8.04 μm for FS1 to FS3; 6.69 to 9.12μm for FS4 to FS6 and 8.22 to 13.32 μm 
for FS7 to FS9 formulations. The size distribution was in the range of 2 to 14 μm. The 
result suggests that  hydrated proniosomes prepared were of uniform size and 
spherical in shape. The microphotographs of all hydrated proniosomal formulations 
reveal that the niosomes were spherical in their shape. From these results the vesicle 
size were found to increase with increase in the concentration of  surfactant
40
. 
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Figure 20: Drug Content of Lamivudine proniosome powder 
 
 
Figure 21: Entrapment Efficiency of Lamivudine proniosome powder 
 
 
 
 
 The Lamivudine  proniosomes were prepared at various  surfactant  
concentrations. The percentage entrapment efficiency was found to be in the range of 
76.24 to 95.02  for FS1 to FS3; 82.05 to 85.54 for FS4 to FS6; 45  to 86.85  for FS7 to 
FS9 formulations. Higher surfactant concentration of span 60, span 40 and Tween 60 
shows higher entrapment efficiency which might be due to the high fluidity of the 
vesicles 
27
. The entrapment efficiency was increase with increasing surfactant 
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concentration. The larger vesicle size may also contribute to the higher entrapment 
efficiency. The highest entrapment efficiency was observed with Span 40 ( FS3) 
formulation . This may be due to the higher HLB value of Span 40 compared to Span 
60. Tween 60 niosomes showed comparatively very low entrapment efficiency which 
may be due to the very high HLB value 14.9 of Tween 60. The results  coinside with 
earlier reports
27,29,80. 
 
The order of non ionic surfactants that resulted in better entrapment efficiency was 
as follows: 
                    Span 40> Span 60> Tween 60 
 
IN- VITRO RELEASE STUDY
 
The in-vitro release study of Lamivudine proniosomes was carried out 
using dialysis membrane in an open ended tube- beaker assembly using distilled 
water as the diffusion medium. 
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Table 21: In- vitro release of proniosomes containing Span 40 in different ratios 
Time in 
hours 
Cumulative % drug release 
 Control FS1 FS2 FS3 
0 0 0 0 0 
0.5 - 34.46 35.08 8.8 
1 64.23 47.61 49.95 14.22 
1.5 - 58.08 53.26 18.53 
2 85.53 64.46 66.31 21.82 
2.5 - 69.58 73.06 26.90 
3 105.5 74.98 78.11 30.58 
3.5 - 77.73 82.31 33.35 
4 - 84.28 89.09 36.69 
4.5 - 90.98 98.45 40.55 
5 - 97.58 102.88 44.39 
6 - 99.23 - 48.68 
7 - - - - 
8 - - - - 
9 - - - - 
10 - - - - 
11 - - - - 
12 - - - - 
18 - - - 58.94 
19 - - - 64.47 
20 - - - 72.86 
21 - - - 78.46 
22 - - - 83.65 
23 - - - 86.66 
24 - - - 93.53 
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Table 22: In- vitro release of proniosomes containing Span 60 in different ratios 
Time in 
hours 
Cumulative % drug release 
 Control FS4 FS5 FS6 
0 0 0 0 0 
0.5 - 18.37 15.25 21.25 
1 64.23 22.36 23.31 25.58 
1.5 - 27.13 30.91 29.16 
2 85.53 31.16 37.21 31.48 
2.5 - 34.83 44.75 34.83 
3 105.5 39.58 48.85 39.66 
3.5 - 42.06 50.76 43.98 
4 - 45.35 60.78 49.45 
4.5 - 63.58 63.06 54.45 
5 - 58.23 65.63 57.18 
6 - 66.43 72.21 63.21 
7 - 70.96 77.21 68.40 
8 - 76.71 87.21 75.68 
9 - 85.40 89.63 84.35 
10 - 93.15 95.61 89.91 
11 - 100.1 99.56 94.21 
12 - - - 97.96 
24 - - - - 
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       Table 23: In- vitro release of proniosomes containing Tween60 in different 
ratios 
 
Time in 
hours 
Cumulative % drug release 
 Control FS7 FS8 FS9 
0 0 0 0 0 
0.5 - 30.16 24.75 18.91 
1 64.23 47.51 36.15 22.36 
1.5 - 62.45 41.86 27.15 
2 85.53 74.33 49.33 31.75 
2.5 - 80.01 59.31 36.03 
3 105.5 87.03 63.58 39.81 
3.5 - 89.25 66.93 42.86 
4 - 94.38 77.33 47.58 
4.5 - 98.16 86.01 52.71 
5 - - 92.01 57.73 
6 - - 102.1 64.61 
7 - - - 76.83 
8 - - - 83.46 
9 - - - 90.71 
10 - - - 98.03 
11 -             - - - 
12 - - - - 
24 - - - - 
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Figure 22: In- vitro release of proniosomes containing Span 40 in different ratios 
 
 
 
 
Figure23: In- vitrorelease of proniosomes containing Span 60 in different ratios 
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Figure 24: In- vitro release of proniosomes containing Tween 60 in different 
ratios 
 
 
 
Figure 25: Comparison of in- vitro release of proniosomes with highest 
entrapment efficiency 
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The  lamivudine proniosomes were prepared at various concentration of 
surfactants. The  cumulative percentage drug release was found to be in the range of 
34.46 to 99.23  for FS1 to FS3; 97.96 to 100 for FS4 to FS6; 98.03  to 102  for FS7 to 
FS9 formulations. Higher surfactant concentration of Span 60, Span 40 and Tween 60 
showed higher entrapment efficiency and more sustained release. The more sustained 
drug release was observed with Span 40 ( FS3) . This may be due to the higher 
entrapment efficiency. The FS3 formulation showed sustained release  of 93.53% 
over 24 hours. The results coinside with earlier reports 
27,29,80
. 
 
 
                All the proniosomal formulations showed sustained release when compared 
with control. 
  
            The cumulative % drug release at 24 hours for different ratios of the three 
non- ionic surfactants was in the following order: 
 
Span 40   : FS1>FS2>FS3 
Span 60   :  FS4>FS5>FS6 
Tween 60   : FS7>FS8>FS9 
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EVALUATION RESULTS OF LAMIVUDINE PRONIOSOMES BY 
COACERVATION PHASE SEPARATION  METHOD 
Table 24:Formulation table 
 
 
 
 
 
FORMULATION   
CODE 
NON – IONIC 
SURFACTANT 
DRUG 
(mg) 
LECITHIN: 
SURFACTANT: 
CHOLESTEROL 
(mg) 
FC1  
 
SPAN 40 
300 100:100:100 
FC2 300 100:200:100 
FC3 300 100:300:100 
FC4  
 
SPAN 60 
300 100:100:100 
FC5 300 100:200:100 
FC6 300 100:300:100 
FC7  
 
TWEEN 60 
300 100:100:100 
FC8 300 100:200:100 
FC9 300 100:300:100 
Results and Discussion 
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Table 25: Mean vesicle size, drug content and entrapment efficiency of 
lamivudine proniosomes by coacervation phase separation method 
 
FORMULATION   
CODE 
NON – IONIC 
SURFACTANT 
MEAN 
VESICLE 
SIZE 
(µm) 
% DRUG 
CONTENT 
(% w/w) 
% 
ENTRAPMENT 
EFFICIENCY 
(% w/w) 
FC1  
 
SPAN 40 
6.24 87.94 33.68 
FC2 7.95 97.26 35.78 
FC3 9.06 84.68 51.51 
FC4  
 
SPAN 60 
8.25 95.86 51.34 
FC5 12.69 97.26 63.06 
FC6 14.13 90.74 77.89 
FC7  
 
TWEEN 60 
7.47 87.48 50.38 
FC8 10.23 93.08 60.39 
FC9 11.94 73.02 73.78 
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Figure 26:  Particle size distribution of Lamivudine proniosome gel 
 
 
 
 
 Lamivudine proniosome gel  prepared using Span 40, Span 60 and Tween 60 
at various concentrations . The  particle size of the  proniosomes  gel was measured 
using an binocular microscope with calibrated eyepiece micrometer. From every 
batch about 100 vesicle were measured for the individually and the average diameter 
was calculated. The average vesicular size of hydrated proniosomes was  in the range 
of 6.24 to 9.06 μm for FC1 to FC3; 8.25 to 14.13 μm for FC4 to FC6 and 7.47 to 
11.94 μm for FC7 to FC9 formulations. The size distribution was in the range of 6  to 
15 μm. The result suggests that proniosomes prepared were of uniform size and 
spherical in shape. The microphotographs of all hydrated  proniosomal formulations 
reveal that the niosomes were spherical in their shape. From these results the vesicle 
size were found to be increase with increase in the concentration of surfactant 
40
. 
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Figure 27: Drug Content of Lamivudine proniosome gel 
 
 
 
 
Figure 28: Entrapment Efficiency of Lamivudine proniosome gel 
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The entrapment efficiency of proniosomes gel prepared  at various 
concentration of surfactants . The percentage entrapment efficiency was found to be 
in the range of 33.68 to 51.51  for FC1 to FC3; 51.34 to 77.89 for FC4 to FC6; 50.38  
to 73.78 for FC7 to FC9 formulations. Higher surfactant concentration of Span 60, 
Span 40 and Tween 60 showed higher entrapment efficiency which might be due to 
the high fluidity of the vesicles. The entrapment efficiency was increased with 
increasing surfactant concentration. The larger vesicle size may also contribute to the 
higher entrapment efficiency. The highest entrapment efficiency was observed with 
Span 60 ( FC6) . This may be due to the high phase temperature of Span 60 compared 
to Span 40 and Tween 60 . This results coinside with earlier reports 
42,46,48
. 
 
The order of non ionic surfactants that resulted in better entrapment efficiency was 
as follows: 
                    Span 60>  Tween 60> Span 40 
 
IN- VITRO RELEASE STUDY
 
 
The in- vitro release study of Lamivudine proniosomes gel was carried out 
using dialysis membrane in an open ended tube- beaker assembly using distilled water 
as the diffusion medium. 
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Table 26: In- vitro release of proniosomes containing Span 40 in different ratios 
Time in 
hours 
Cumulative % drug release 
 Control FC1 FC2 FC3 
0 0 0 0 0 
0.5 - 10.58 5.91 8.45 
1 64.23 12.53 7.21 9.59 
1.5 -         12.95 9.25 11.31 
2 85.53 15.11 12.35 12.91 
2.5 - 17.98 11.25 14.91 
3 105.5 22.16 13.81 16.17 
3.5 - 19.66 16.38 19.77 
4 - 20.43 19.03 22.28 
4.5 - 21.12 20.88 23.46 
5 - 22.51 22.26 24.86 
6 - 25.06 24.83 27.06 
7 - 25.68 26.21 30.06 
8 - 24.06 29.81 31.95 
9 - 28.53 33.01 34.65 
10 - 29.93 37.35 37.00 
11 - 31.26 41.66 39.77 
12 - 33.86 43.15 42.78 
24 - 39.91 47.63 49.73 
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Table 27: In- vitro release of proniosomes containing Span 60 in different ratios 
 
Time in 
hours 
Cumulative % drug release 
 Control FC4 FC5 FC6 
0 0 0 0 0 
0.5 - 8.81 6.51 8.25 
1 64.23 9.76 8.83 10.49 
1.5 - 12.28 12.41 13.28 
2 85.53 14.85 15.41 16.04 
2.5 - 17.47 18.41 18.68 
3 105.5 18.97 21.29 21.37 
3.5 - 21.49 23.45 23.94 
4 - 23.06 25.47 26.47 
4.5 - 24.81 29.02 28.54 
5 - 25.68 30.88 31.56 
6 - 28.80 34.02 35.46 
7 - 30.31 36.96 38.84 
8 - 32.17 40.86 44.37 
9 - 34.48 43.00 51.99 
10 - 37.82 45.09 57.74 
11 - 40.05 46.61 62.85 
12 - 44.81 49.15 66.87 
24 - 53.16 58.39 72.44 
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Table 28: In- vitro release of proniosomes containing Tween 60 in different ratios 
 
Time in 
hours 
Cumulative % drug release 
 Control FC7 FC8 FC9 
0 0 0 0 0 
0.5 - 7.09 7.41 7.61 
1 64.23 7.81 9.31 8.91 
1.5 - 12.13 12.65 10.01 
2 85.53 13.41 14.65 11.85 
2.5 - 15.23 17.43 13.61 
3 105.5 17.85 18.35 15.10 
3.5 - 19.15 21.03 17.12 
4 - 22.04 24.33 19.19 
4.5 - 24.20 26.53 21.04 
5 - 25.80 27.61 24.75 
6 - 27.63 30.85 29.70 
7 - 29.67 32.15 34.91 
8 - 32.53 33.15 39.96 
9 - 33.49 37.21 45.56 
10 - 36.98 38.18 50.49 
11 -         38.78 39.66 54.06 
12 - 40.45 41.08          58.51 
24 - 45.37 51.26 67.70 
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Figure 29: In- vitro release of proniosomes containing Span 40 in different ratios 
 
 
 
 
Figure 30: In- vitro release of proniosomes containing Span 60 in different ratios 
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Figure 31: In- vitro release of proniosomes containing Tween 60 in different 
ratios 
 
 
 
Figure 32: Comparison of in- vitro release of proniosomes with highest 
entrapment efficiency 
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The in-vitro release of Lamivudine  proniosomes gel were prepared at various 
concentration of surfactants. The  cumulative percentage  of drug release was found to 
be in the range of 39.91 to 49.73  for FC1 to FC3; 53.16 to 72.44 for FC4 to FC6; 
45.37  to 67.70  for FC7 to FC9 formulations. Higher surfactant concentration of Span 
60, Span 40 and Tween 60 showed higher entrapment efficiency and more sustained 
release. The more sustained drug release was observed with Span 60 ( FC6) . This 
may be due to the higher entrapment efficiency. The FC6 formulation showed 
sustained release of 72.44%  over 24 hours. This results coinside with earlier 
reports
46,48
. 
 
 
                All the proniosomal formulations showed sustained release when compared 
with control. 
  
            The cumulative % drug release at 24 hours for different ratios of the three 
non- ionic surfactants was in the following order: 
 
Span 40 : FC1>FC2>FC3 
Span 60 : FC4>FC5>FC6 
Tween 60 : FC7>FC8>FC9 
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COMPARISION OF  OF LAMIVUDINE PRONIOSOMES 
PREPARED BY SLURRY AND COACERVATION PHASE 
SEPARATION METHODS 
 
 
Table 29: Comparision of entrapment efficiency of Lamivudine proniosomes  
 
 
Non – Ionic 
Surfactant 
Formulation   
Code 
% 
Entrapment 
Efficiency 
(% W/W) 
Formulation   
Code 
% 
Entrapment 
Efficiency 
(% W/W) 
 
 
SPAN 40 
FS1 76.24 
 
FC1 33.68 
FS2 71.13 FC2 35.78 
FS3 95.02 FC3 51.51 
 
 
SPAN 60 
FS4 82.05 FC4 51.34 
FS5 83.33 FC5 63.06 
FS6 85.54 FC6 77.89 
 
 
TWEEN 60 
FS7 45 FC7 50.38 
FS8 55.86 FC8 60.39 
FS9 86.85 FC9 73.78 
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Table 30: Comparision of in-vitro drug release (at 24 th hour) of lamivudine 
proniosomes  
 
 
Non – Ionic 
Surfactant 
Formulation   
Code 
Cumulative 
% drug 
release 
(% W/W) 
Formulation   
Code 
Cumulative % 
drug release 
(% W/W) 
 
 
SPAN 40 
FS1 - 
 
FC1 39.91 
FS2 - FC2 47.63 
FS3 93.53 FC3 49.73 
 
 
SPAN 60 
FS4 - FC4 53.16 
FS5 - FC5 58.39 
FS6 - FC6 72.44 
 
 
TWEEN 60 
FS7 - FC7 45.37 
FS8 - FC8 51.26 
FS9 - FC9 67.70 
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Table 33: Comparision of in-vitro drug release of  optimized lamivudine 
proniosomes 
 
 
 
 
 
The cumulative percentage of drug release of the optimized formulation of 
Lamivudine proniosome powder (FS3) and proniosome gel  (FC6) were compared. 
From these results the FS3 formulation showed more sustained release over 24 hours  
when compared to FC6 formulation due to the higher entrapment efficiency of FS3 
formulation (95.02%). 
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EFFECT OF SURFACTANT CONCENTRATION ON VESICLE 
SIZE 
 The  vesicle size of the hydrated proniosome powder and gel was measured 
using a binocular microscope with calibrated eyepiece micrometer. From 
every batch about 100 vesicles were measured individually and then average  
diameter was calculated. 
 The result suggests that  hydrated proniosome powder and gel were of uniform 
size. The microphotographs of all  proniosomal formulations reveal that the 
niosomes were spherical in their shape.   
 From these results the vesicle size was found to  increase with increase in the 
concentration of surfactant. 
 
Among the formulations prepared by two methods using Span 40 the 
vesicle size were found to increase with increase in the concentration of 
surfactant .The increase in vesicle size was found to be in the following order 
 
FS1>FS2>FS3 
FC1>FC2>FC3 
 Among the formulations prepared by two methods using Span 60 the 
vesicle size were found to increase with increase in the concentration of 
surfactant . The increase in vesicle size was found to be in the order  
 
FS4>FS5>FS6 
FC4>FC4>FC6 
    Among the formulations prepared by two methods using Tween 60 the  
vesicle size were found to  increase with increase in the  concentration  of 
surfactant. The increase in vesicle size was found to be in the order 
 
FS7>FS8>FS9 
FC7>FC8>FC9 
 
Results and Discussion 
 
MADRAS MEDICAL COLLEGE  DEPARTMENT OF PHARMACEUTICS 134 
EFFECT OF SURFACTANT CONCENTRATION ON 
ENTRAPMENT EFFICIENCY 
 The Lamivudine  proniosomes were prepared at various  surfactant 
concentrations. 
 Higher surfactant concentration of span 60, span 40 and Tween 60 showed 
higher entrapment efficiency which might be due to the high fluidity of the 
vesicles 
27
. 
 The entrapment efficiency  increase with increasing  surfactant concentration. 
Among the formulations prepared by two methods using Span 40 the % 
entrapment efficiency were found to increase with increase in the concentration of 
surfactant. The increase in % entrapment efficiency was found to be in the order of 
FS1>FS2>FS3 
FC1>FC2>FC3 
Among the formulations prepared by two methods using Span 60 the % 
entrapment efficiency were found to increase with increase in the concentration of 
surfactant. The increase in  % entrapment efficiency was found to be in the order of                    
FS4>FS5>FS6 
FC4>FC4>FC6 
Among the formulations prepared by two methods using Tween 60 the% 
entrapment efficiency were found to  increase with increase in  the concentration of 
surfactant. The increase in  % entrapment efficiency was found to be in the order of 
 
  
FS7>FS8>FS9 
FC7>FC8>FC9 
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EFFECT OF SURFACTANT CONCENTRATION ON DRUG 
RELEASE 
o The  Lamivudine proniosomes were prepared at various concentration 
of surfactants. 
o Higher surfactant concentration of Span 60, Span 40 and Tween 60 
showed more sustained release due to higher entrapment efficiency.  
o The cumulative percentage drug release more sustained with increasing 
the concentration of surfactant. 
Among the formulations prepared by two methods using Span 40 the 
cumulative % drug release were found to increase with increase in the concentration 
of surfactant. The increase in % drug release was found to be in the order 
FS1>FS2>FS3 
FC1>FC2>FC3 
Among the formulations prepared by two methods using Span 60 the   
cumulative % drug release were found to increase with increase in the concentration 
of surfactant. The increase % drug release was found to be in the order 
 
FS4>FS5>FS6 
FC4>FC4>FC6 
Among the formulations prepared by two methods using Tween 60 the 
cumulative % drug release were found to  increase with increase in the concentration 
of surfactant. The increase in the cumulative % drug release was found to be in the 
order 
         FS7>FS8>FS9 
FC7>FC8>FC9 
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KINETICS OF DRUG RELEASE 
The in- vitro release data was applied to various kinetic models to predict 
the mechanism of drug release of the optimized formulation FS3  
Table 31: Kinetics Data 
Time 
in 
hours 
% 
cumulative 
drug 
release 
Log % 
cumulative 
drug 
release 
Sq.root 
of time 
Log 
time 
% drug 
remaining 
Cube root 
of drug 
remaining 
Log % 
drug 
remaining 
0 0 -∞ 0 -∞ 100 4.64 2 
0.5 8.8 0.944 0.707 -
0.301 
91.21 4.501 1.959 
1 14.22 1.152 1 0 85.78 4.410 1.933 
1.5 18.53 1.267 1.224 0.176 81.42 4.334 1.910 
2 21.82 1.338 1.414 0.301 78.59 4.283 1.895 
2.5 26.90 1.429 1.581 0.397 73.11 4.181 1.863 
3 30.58 1.485 1.732 0.477 69.42 4.109 1.841 
3.5 33.35 1.523 1.870 0.544 66.65 4.054 1.823 
4 36.69 1.564 2 0.602 63.31 3.985 1.801 
4.5 40.55 1.607 2.121 0.653 59.45 3.902 1.774 
5 44.39 1.647 2.236 0.698 55.61 3.816 1.745 
6 48.68 1.687 2.449 0.778 51.32 3.716 1.710 
18 58.98 1.770 4.242 1.255 41.06 3.449 1.613 
19 64.41 1.808 4.358 1.278 35.53 3.287 1.550 
20 72.46 1.862 4.472 1.301 27.54 3.005 1.433 
21 78.46 1.894 4.582 1.322 21.54 2.782 1.333 
22 83.65 1.922 4.690 1.342 16.35 2.538 1.213 
23 86.66 1.937 4.795 1.361 13.34 2.371 1.125 
24 93.53 1.970 4.898 1.380 6.47 1.863 0.810 
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Figure 34: Zero- Order Release Kinetics of  FS3 
 
 
 
                       Figure 35: First Order Release Kinetics of FS3 
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Figure 36: Higuchi Model Kinetics of FS3 
 
 
 
                       Figure 37: Hixson Crowell Model Kinetics of FS3 
 
 
 
 
 
y = 17.136x - 0.005 
R² = 0.9603 
-20
0
20
40
60
80
100
0 1 2 3 4 5 6
%
 C
u
m
u
la
ti
ve
 d
ru
g 
re
le
as
e
 
Square root of time 
Higuchi diffusion kinetics 
y = -0.0822x + 4.4242 
R² = 0.9062 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 5 10 15 20 25 30
C
u
b
e
 r
o
o
t 
o
f 
5
 d
ru
g 
re
m
ai
n
in
g 
Time in hours 
Hixson crowell release kinetics 
Results and Discussion 
 
MADRAS MEDICAL COLLEGE  DEPARTMENT OF PHARMACEUTICS 139 
 
 
Figure 38: Korsemeyer- Peppas Model Kinetics of FS3 
 
 
 
The regression coefficient (r
2
) was determined using the drug release data. 
The results are shown in Table 32. 
Table 32: Drug Release Kinetics 
FORMULATI
ON CODE 
ZERO 
ORDER 
FIRST 
ORDER 
HIGUCHI 
MODEL 
KORSEMEYER 
PEPPAS 
HIXSON 
CROWELL 
R
2 
R
2 
R
2 
R
2 
n R
2 
FS3 0.901 0.856 0.960 0.966 0.543 0.906 
 
The drug release pattern from Lamivudine loaded Proniosome (FC3) follows 
Korsemeyer peppas and Higuchi model. The value of the krosemeyer peppas model 
for FS3 was found to be 0.543 . Which confirm the Non-fickian  type diffusion (or) 
anamalous  diffusion mechanism 
27
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STABILITY STUDIES OF LAMIVUDINE PRONIOSOMES 
  
Stability studies of the optimized formulation FS3 were carried out by storing 
at  4 0C ± 2 0 C (refrigeration temperature) and 250C ±  2 0C for a period of  45 days. 
 
Table 33: Stability Study of Lamivudine Proniosomes – Optimized Formulation FS3 
 
 
Time of 
storage in 
days 
Temperature of storage 
4 0C ± 2 0 C (Refrigerator 
temperature) 
4 0C ± 2 0 C (Room 
temperature) 
Drug 
content(%) 
Entrapment 
efficiency(%) 
Drug 
content(%) 
Entrapment 
efficiency(% 
0 90.67 95.02 90.67 95.02 
15 90.50 94.52 88.53 93.21 
30 90.22 94.11 87.20 90.32 
45 89.91 93.72 84.31 89.81 
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Figure 39 :Stability of optimized formulation % drug content analysis 
 
 
 
Figure 40:Stability of optimized formulation % Entrapment efficiency 
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Stability studies of the optimized formulation FS3 were carried out by storing 
at 4 0C ± 2 0C (refrigeration temperature) and 4 0C ± 2 0C for a period of  45 days. 
The drug leakage from the vesicles was least at 4
0 
C. This may be attributed to phase 
transition of non-ionic surfactant and lipid causing leakage of vesicles at higher 
temperatures during storage. Hence the proniosomes can be stored at 4 
0 
C. This 
results coinside with earlier reports 
10,30
. 
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SCANNING ELECTRON MICROSCOPY 
 
SEM image of optimized proniosomal formulations were recorded. The 
particles are almost spherical and homogeneous. The results showed that the 
Lamivudine loaded proniosomes have a spherical shape with smooth surface and 
discrete without any aggregation or agglomeration. 
Figure 41: Optimized  Lamivudineproniosome powder (FS3) 
 
 
 
Figure 42: Photomicroscopy of FS3 
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Figure 43: Optimized Lamivudine proniosome gel (FC6) 
 
 
 
 
 
 
Figure 44: Photomicroscopy of FC6 
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10. SUMMARY AND CONCLUSION 
 The purpose of this research was to formulate Lamivudine proniosome drug 
delivery system by coacervation phase separation and slurry method using 
different non-ionic surfactants. 
 The formulations were prepared using different non ionic surfactants in 
various the surfactant concentrations (Span 40, Span 60 and Tween 60) 
keeping the concentration of Cholesterol, Maltodextrin, Lecithin as constant. 
 The prepared Lamivudine powder by slurry and Lamivudine gel by 
coacervation phase separation method were characterized for entrapment 
efficiency and mean vesicle diameter (MVD). 
 The percentage drug entrapment of Lamivudine powder ranged from 45 to 
95.02%. 
 The percentage drug entrapment of Lamivudine gel ranged from 33.68 to 
77.89%. 
 The cumulative percentage of drug release at (24th hour) of optimized 
Lamivudine powder was (FS3) 93.53% and optimized Lamivudine gel  was 
(FC6) 72.44% . 
 From the resultant  entrapment efficiency and in-vitro drug release data, slurry 
method is better than coacervation method to formulate Lamivudine 
proniosomes. 
 The order of entrapment efficiency of the proniosome powder. 
Span 40 > Span 60> Tween 60 
 The order of entrapment efficiency of the proniosome gel 
Span 60 > Tween 60 > Span 40 
 The order of in vitro drug release of the proniosome powder 
           Span 40 > Span 60>Tween 60 
 The order of in vitro drug release of the proniosome gel 
Span 60 > Tween 60 > Span 40 
 From these resulat sustained drug release strongly influenced by entrapment 
efficiency. 
 From all these formulations FS3 prepared by slurry method was optimized 
which had better entrapment efficiency (95.02%) and  better sustained release 
over 24 hours ( 93.53%). 
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 Effect of surfactant concentration on vesicle size was studied. The vesicle size 
increased with increase in the surfactant concentration. 
 Effect of surfactant concentration on entrapment efficiency was studied. The 
entrapment efficiency increased with increase in the surfactant concentration. 
 Effect of surfactant concentration on rate of drug release was studied. The     
more sustained drug release was observed with increase in the surfactant 
concentration. 
 SEM analysis of the optimized proniosome powder (FS3) showed the 
spherical shape of the vesicles. 
 The drug release pattern from Lamivudine loaded Proniosome (FC3) follows 
Korsemeyer peppas and Higuchi model . 
 The results of FT-IR studies proved that there is no interaction between the 
drug and Excipients. 
 From the stability studies, the optimum storage condition for Lamivudine 
proniosome was found to be 4
°
C. 
. 
 
 
FUTURE SCOPE 
 The Lamivudine proniosome powder formulation may be designed into 
suitable delivery systems such as tablet, capsule forms. 
 The Lamivudine proniosome gel formulation may be designed into suitable 
delivery systems such as transdermal form. 
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